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ABSTRACT 
 
 
Cryptococcus neoformans is an opportunistic fungal pathogen that primarily 
infects the immunocompromised. It is responsible for approximately 180,000 
deaths per year in individuals with HIV. Fluconazole (FLC) is a fungistatic drug 
widely used to treat cryptococcosis and prevent recurrence. C. neoformans 
exhibits an intrinsic heteroresistance to FLC, which is an emerging barrier to 
effective treatment especially in resource-limited regions where FLC is often the 
only therapy available. Previous studies have demonstrated that C. neoformans 
cells confer resistance to FLC through aneuploid formation. The mechanisms 
underlying aneuploid formation during FLC treatment are unknown.  
This dissertation characterizes the effects of the initial exposure to FLC, 
which is critical to development of aneuploidy and resistance in C. neoformans. It 
highlights the unique mitotic cycle of C. neoformans, providing evidence that the 
ploidy increase during FLC treatment is likely due to the progression of nuclear 
division despite inhibition of cellular growth. It shows FLC inhibits budding and 
cytokinesis, producing cells with aberrant morphologies that exhibit increased 
ploidy levels. Furthermore, through cell sorting and microdissection analysis it 
highlights the role of multibudded cells or “multimeras” in promoting proliferation 
during FLC therapy. It provides support that FLC produces a widespread increase 
in ploidy from which aneuploids could then potentially be selected.  
Additionally, this dissertation further characterizes the phenomenon of 
heteroresistance through single cell and colony level analyses. Filipin staining 
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displays the unequal depletion of ergosterol between individual cells within a 
population, highlighting the heterogeneous response within a population to FLC. It 
further explores the heterogeneity of FLC-treated cells within a population through 
colony size analysis. Interestingly, factors that influence slower growth promote 
the proliferation of resistant cells and also the proliferation of cells we refer to as 
“survivors.” Survivors are characterized by their ability to form small colonies on 
FLC, while not exhibiting the fitness tradeoff seen in resistant cells. It provides a 
thorough analysis of the response of C. neoformans to FLC and proposes a model 
that summarizes the factors that contribute to growth during FLC treatment.  
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CHAPTER ONE 
 
LITERATURE REVIEW 
 
 
 
 
 
A portion of this review was previously published – Altamirano, S, 
Chandrasekaran, S., Kozubowski, L. 2017. Mechanisms of Cytokinesis in 
Basidiomycetous Yeasts. Fungal Biol Rev 2:73—87. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 2 
CRYPTOCOCCUS NEOFORMANS: A BASIDIOMYCETEOUS, HUMAN 
PATHOGEN 
The Mitotic Cycle and Cytokinesis of the Yeast Form of C. neoformans 
Cryptococcus neoformans is a member of Agaricomycotina in the second largest 
fungal phylum, Basidiomycota. It can undergo both asexual and sexual 
reproduction. Sexual reproduction occurs through a bipolar mating system (mating 
type a and alpha). During the sexual cycle, mating results in dikaryotic hyphae 
formation. The basidium is then formed where nuclei fusion and meiosis occurs. 
After meiosis, mitotic divisions occur that result in spore formation that bud from 
the basidium surface producing four spore chains (1). Despite is ability to form 
hyphae, C. neoformans is predominantly a haploid yeast that reproduces asexually 
via budding, and it is the yeast form that causes infection (2). The mitotic cycle and 
cytokinesis in C. neoformans remain largely unexplored. The mechanisms of 
mitosis and cytokinesis in yeast are largely based on the more thoroughly studied 
budding yeast, Saccharomyces cerevisiae, and the fission yeast, 
Schizosaccharomyces pombe. Both of these model yeasts are ascomycetes that 
likely exhibit similarities and differences in cell division compared to the 
basidiomycete, C. neoformans. In addition to potentially highlighting new 
therapeutic targets against cryptococcosis, studying the cell cycle of the yeast form 
of C. neoformans may be critical in better understanding the evolution of the 
mechanisms of mitosis and cytokinesis.     
During mitosis, a mother cell undergoes nuclear division and gives rise to a 
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genetically identical daughter cell. Mitosis is a highly-regulated process that 
ensures accurate and equal chromosome segregation between the daughter and 
mother cell. Kinetochores play a crucial role in chromosome segregation by linking 
centromeres to spindle microtubules, which then pull sister chromatids to separate 
cellular poles. The kinetochore consists of trilaminar plates referred to as the inner, 
middle, and outer layers that surround the centromeric DNA. The architecture of 
kinetochores is thought to be conserved from yeast to animals (3). A recent study 
in C. neoformans identified six putative kinetochore homologs corresponding to 
each of the three layers, suggesting that the kinetochore architecture is also 
conserved in C. neoformans. Time-lapse microscopy utilizing the Mif2 inner layer 
homologue, the Mis12/Mtw1 middle layer homologue, and the Dad1 outer layer 
homologue showed that prior to mitosis, kinetochores in C. neoformans undergo 
a step-wide assembly. Utilizing a strain expressing fluorescently-labelled tubulin 
and fluorescently-labelled homologue of CENP-A, Cse4, to visualize the 
centromeres, the microtubule-kinetochore attachment was also established to only 
occur during mitosis (4, Figure 1.1). The kinetochore dynamics of C. neoformans 
appear to more closely resemble metazoans than other yeast. In metazoans, 
kinetochores also assemble in a step-wise manner and the kinetochore-
microtubule attachment does not persist throughout mitosis, whereas the 
kinetochores of S. cerevisiae are fully-assembled and remain attached to 
microtubules throughout the cell cycle, except a brief reassembly during replication 
(5–8).  
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The kinetochore-microtubule attachment takes place only during mitosis in 
metazoans due to the fact that the microtubule organizing centers localize outside 
the nuclear envelope. A complete breakdown of the nuclear envelope, known as 
open mitosis, has to occur to allow the attachment of kinetochores with 
microtubules (9). In contrast, S. cerevisiae undergoes a closed mitosis, where the 
nuclear envelope remains intact. Closed mitosis allows spindle pole bodies 
(SPBs), the equivalent of the microtubule organizing centers in yeast, to remain 
attached to the nuclear envelope and in constant contact with kinetochores (10). 
Consistent with metazoan-like dynamics of the kinetochores, C. neoformans 
undergoes an intermediate type of cell division known as semi-open mitosis, where 
the nuclear envelope partially breaks open during mitosis (4, Figure 1.1). An 
additional strikingly distinct feature of mitosis in C. neoformans is the translocation 
of all of the chromatin to the daughter cell where the spindle is formed. Segregation 
of chromosomes then proceeds in the direction from the bud into the mother cell 
(4, Figure 1.1). The seemingly energy-inefficient process of nuclear division in the 
daughter cell does not occur in ascomycetes, but it appears to be characteristic of 
other basidiomycetes (4, 11).   
Cytokinesis is the final step in the cell cycle that results in two physically 
separate cytoplasms of the dividing cells. How cytokinesis is activated in C. 
neoformans is presently unknown. Given the unique nuclear division of C. 
neoformans, mechanisms of entry into cytokinesis may also demonstrate a 
significant divergence. In S. cerevisiae, the entry to cytokinesis is regulated 
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through the signaling dependent on the Polo kinase and a network of proteins 
collectively known as the Mitotic Exit Network (MEN) (12–15). MEN signaling 
initiates during late anaphase at the SPB where the GTPase, Tem1, stimulates the 
kinase, Cdc15, to activate the Mob1-Dbf2 kinase complex. Mob1-Dbf2 in turn 
promotes the release of the protein phosphatase, Cdc14, from the nucleolus. 
Cdc14 reverses phosphorylation of a number of Cdk1 targets, leading to mitotic 
exit and cytokinesis (16, 17). It is puzzling how a signaling based on Cdc14 release 
from the nucleolus would operate in C. neoformans given that the nucleolus 
disintegration initiates before the spindle assembles (4). Furthermore, a spindle 
position checkpoint could not operate in C. neoformans if the Cdc14 were released 
from nucleolus and signaled to start cytokinesis before metaphase (18). One 
possibility is that Cdc14-based signaling similar to MEN is not conserved in C. 
neoformans. On the other hand, C. neoformans contains a homologue of the 
Cdc14 phosphatase and other typical MEN components (Table 1.1). Cdc14-like 
phosphatases are likely critical for the mitotic exit control in metazoans and may 
localize to the nucleolus (19, 20). Therefore, the Cdc14 homologue may act in the 
mitotic exit network in C. neoformans via mechanisms similar to that occurring in 
metazoans.  
An important component in the process of cytokinesis, conserved in fungi 
and metazoans, is the actomyosin ring (AMR). The AMR is composed of myosin II 
(heavy, light, and regulatory chains) and filamentous actin (F-actin) (21). Non-
muscle myosin II is the essential motor that drives actin-based cytokinesis (22). 
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The antiparallel filaments of actin in the AMR undergo a continuous cycle of 
nucleation, polymerization, and depolymerization (23). In C. neoformans, Myo1, 
the myosin II heavy chain, localizes to the bud neck and constricts similarly to the 
S. cerevisiae homologue (24). The F-actin localization and dynamics in C. 
neoformans appear similar to S. cerevisiae (25). While tropomyosins have not 
been thoroughly described in basidiomycetes, C. neoformans mutants lacking 
formin or tropomyosin homologues exhibit defects in cytokinesis (26). Thus, it is 
likely that the AMR in C. neoformans would have a similar architecture to the AMR 
in ascomycetes.  
In fungi, an important part of cytokinesis is the formation of the future cell 
wall between the mother and the daughter cell. In C. neoformans, similar to 
ascomycetous yeasts, an initial cell wall is produced in the form of a primary 
septum and subsequently two secondary septa are formed on each side of the 
primary septum (27). The fungal septum is made of a cell wall-like material that 
ultimately forms a physical barrier separating the cytoplasm (28). To allow final cell 
separation, the primary septum is degraded and the secondary septa serve as new 
wall between the dividing cells.  
In model yeasts the AMR constriction is coincidental with the formation of 
the primary septum (29). The primary septum grows centripetally inward as the 
AMR closes. Whether the AMR drives the septum formation directly remains 
unclear. A study by Proctor et al. proposed that in S. pombe the essential 
contribution to cytokinesis of myosin and F-actin is restricted to only an initial part 
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of the constriction process (30). Thus, the major force in cytokinesis is likely 
attributed to the assembly of cell wall polymers in the growing septum; the AMR 
plays only a minor role. Other studies suggest that the optimal AMR constriction 
and primary septum formation are interdependent; AMR guides septum formation, 
while septum formation stabilizes AMR constriction (23, 31–34). Given that all 
fungal cells have cell walls and form septa during cytokinesis it is likely that the 
mechanism of the constriction of the AMR and its relative contribution to 
cytokinesis are conserved in most fungi, including C. neoformans.  
The final daughter cell detachment in fungi is accomplished by the 
concerted action of hydrolytic enzymes that degrade the thin layer of the primary 
septum and is controlled by a highly conserved morphogenesis-related pathway 
(MOR) also known as the RAM (regulation of Ace2 and morphogenesis) pathway 
(35, 36).  In S. cerevisiae, the Ace2 transcription factor accumulates specifically in 
the daughter nucleus and promotes hydrolysis of the septum from the daughter 
side (37). Interestingly no clear homologues of Ace2 are present in the C. 
neoformans genome. This suggests an alternative mechanism for positioning the 
activity of the hydrolytic enzymes specifically on the daughter side. Surprisingly, 
none of the endochitinases encoded by the C. neoformans genome are necessary 
for vegetative growth consistent with an absence of the bud scar in this yeast (38, 
39). As C. neoformans may not have an enzyme that specifically hydrolyzes 
chitosan, an alternative mechanism for daughter cell separation that is based on 
the increased flexibility and solubility of the chitosan has been proposed (39). 
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Epidemiology and Virulence of C. neoformans 
C. neoformans is an opportunistic, fungal pathogen that can cause meningitis 
primarily in immunocompromised individuals. It is the leading mycotic killer of 
individuals with HIV-1. According to recent reports, approximately 220,000 HIV-
related cryptococcal cases occur annually, resulting in 181,000 deaths. The 
majority of cases occur in sub-Sahara Africa where the burden of cryptococcal 
infection is especially high due to the increased prevalence of HIV and the limited 
availability of both anti-retroviral therapy and antifungal drugs (40). 
C. neoformans is a globally distributed pathogen that is commonly found in 
sources of decaying material, such as tree hollows, soil, and pigeon guano (41). 
Despite its ability to colonize humans and non-human hosts, human-to human 
transmission does not occur and zoonotic transmission is rare (42). The primary 
method of transmission is through inhalation of spores or desiccated yeast cells 
from the environment (41). C. neoformans is an opportunistic pathogen that takes 
advantage of the attenuated immune state of its host while also displaying virulent 
phenotypes that promote pathogenicity.  
In healthy individuals, infection results in a state of latency that rarely leads 
to disease. However, in immunocompromised individuals, latent infections are 
likely to advance into disease. Disease is primarily associated with dissemination 
into the central nervous system, marked by fungemia and/or meningitis.  
Pneumonia and skin lesions are also symptoms characteristic of disease (43). The 
ability of C. neoformans to cause disease primarily in patients with compromised 
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immune system highlights the importance of the host immune response in 
preventing cryptococcosis. Studies have shown the critical role of the CD4 T-cell 
mediated response in controlling cryptococcal infection (44). Phagocytosis by 
macrophages and dendritic cells is a key element of the immune system that is 
crucial in controlling initial cryptococcal infection. Depletion of alveolar 
macrophages and dendritic cells results in increased rates of cryptococcal 
dissemination, while neutrophils and B cells alone cannot control infection and may 
instead increase damage to the host (45, 46). 
In addition to taking advantage of the weakened immune system of the host, 
C. neoformans displays virulence factors that allow it to further evade host immune 
recognition. Often referred to as the “sugar-coated killer”, the protective 
polysaccharide capsule of C. neoformans has been shown to be important in 
promoting infection (47). Mutants that fail to produce capsule exhibit a significantly 
attenuated virulence in murine model of cryptococcosis (48).  The polysaccharide 
capsule protects the cell from phagocytosis. Capsular enlargement and increased 
capsular matrix density decrease the deposition of complements or antibodies, 
reducing immune system recognition and phagocytosis (49). Melanization is 
another prominent virulence factor that allows for evasion of the immune system 
in C. neoformans (50). Melanized cells occur during infection and display reduced 
levels of phagocytosis, which is likely due to surface charge effects (51). 
Additionally, melanin synthesis contributes to increased resistance to oxygen and 
nitrogen related stresses, as well as antifungals (52). Metabolic pathways leading 
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to capsule formation and melanin production have been a subject of intense 
studies, with the primary goal of finding new drug targets and development of 
vaccines preventing cryptococcosis (53–55). 
Several studies have also highlighted the significant role of C. neoformans’s 
genome plasticity in promoting pathogenicity (56). During infection, C. neoformans 
is able to produce aneuploid and polyploid cells that likely act as sources of 
adaptive phenotypic change during infection. In vitro and in vivo studies have 
shown that aneuploid formation is responsible for resistance to the commonly used 
azole drug, fluconazole (57, 58). Polyploid cells isolated from the lung, known as 
titan cells, have been shown to be protected from the host’s immune response due 
to their enlarged size and cell surface alterations (59–61). Titan cells and titan 
daughter cells also exhibit increased stress resistance, suggesting these cells are 
critical for host adaptation during infection (62). Despite evidence that the genomic 
plasticity is critical in promoting survival of yeast cells during infection, little is 
known about the mechanisms underlying aneuploid and polyploid formation in C. 
neoformans. The mechanism of aneuploid formation during fluconazole treatment 
is the major subject of this thesis and will be further discussed in subsequent 
chapters.  
 
Diagnosis and Treatment of Cryptococcosis 
Diagnostic methods of cryptococcosis include typical serological and 
histopathological techniques. Histopathology analysis often involves staining to 
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identify virulence factors such as capsule formation and melanization (63). The 
most common diagnostic method is the detection of cryptococcal antigen in serum 
or cerebrospinal fluid using latex agglutination or enzyme immunoassay (64). In 
resource-limited countries these techniques are not always readily accessible. 
Intriguingly, a lateral flow assay has recently been implemented that allows rapid, 
more sensitive detection and is cost effective (65, 66).  
Treatment of cryptococcosis is limited to the following three drugs: 
amphotericin B (AmpB), flucytosine (5FC), and fluconazole (FLC) (63). Treatment 
strategies for cryptococcal infection are based on the severity and site of infection. 
During mild to moderate pulmonary infections, FLC is the preferred method of 
treatment. FLC inhibits the conversion of lanosterol to C-14-demethyl-lanosterol in 
the ergosterol synthesis pathway through binding to the cytochrome P-450 
enzyme, 14-alpha-demethylase, which is encoded by ERG11 (67). FLC is fungal-
specific, resulting in low toxicity levels and is widely available (68). Treatment for 
more severe pulmonary infections and infections of the central nervous system 
consists of a combination therapy of ampB and 5FC. FLC is then administered as 
maintenance therapy (63). AmpB is a fungicidal polyene that binds to ergosterol. 
It is thought to act as a “sterol sponge” that binds and removes ergosterol from the 
membrane (69). 5FC intercalates into fungal RNA, blocking protein synthesis and 
inhibits DNA synthesis through the inhibition of thymidylate synthetase (70). Both 
ampB and 5FC exhibit increased levels of toxicity compared to FLC and are not 
widely available due to relatively high cost.   
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Cost, availability, and toxicity are all major drawbacks of ampB and 5FC 
therapy. In sub-Saharan Africa, where the majority of HIV-related cryptococcal 
cases occur, 5FC is unregistered and the facilities to safely administer ampB are 
often not available (71). These challenges often leave FLC as the primary method 
of treatment in resource-limited countries. FLC is also the preferred drug to 
administer as a form of maintenance therapy. In patients with HIV, prophylactic 
therapy may be lifelong, so the reduced toxicity and cost of FLC make it an ideal 
candidate (72). Despite the advantages of FLC, the widespread use of FLC as a 
primary method of treatment in resource-limited countries and in maintenance 
therapy has led to the increasing problem of FLC resistance (73).  
While several other antifungal drugs are available, their ability to treat C. 
neoformans is not effective or remains to be fully elucidated. The newest class of 
antifungals, the echinocandins, are not recommended due to their inability to treat 
cryptococcosis. Echinocandins are effective in vitro, but are likely not effective in 
vivo likely due to the increased chitin levels of C. neoformans cells in vivo  (74–
77).  Other azoles, such as itraconazole, voriconazole, posaconazole, and 
isavuconazole have shown to be effective in vitro, but there has been limited 
assessment of their clinical use. Itraconazole, voriconazole, and posaconazole 
exhibit poor penetration of the central nervous system. Interestingly, 
isavuconazole showed adequate central nervous system penetration and may be 
advantageous in treating invasive cryptococcal infections, especially considering 
the reduced adverse effects of isavuconazole compared to ampB. Further clinical 
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studies are needed to further assess the efficacy of isavuconazole (78). Until new 
therapies are developed and proven effective, strategies to reduce resistance to 
currently administered antifungals are necessary.  
 
FLUCONAZOLE RESISTANCE 
The Effects of FLC 
As mentioned above, FLC is a cytochrome P450 inhibitor. It targets the cytochrome 
P450 demethylase encoded by ERG11, which is involved in the oxidative 
metabolism of lanosterol in the ergosterol synthesis pathway (67). Ergosterol is a 
sterol found in fungal cellular membranes that is similar to mammalian cholesterol 
and is important in membrane dynamics, including but not limited to membrane 
fluidity, determination of membrane thickness, and endocytosis. It can be found in 
the membranes of all membrane-bound organelles, with the plasma membrane 
containing the highest percentage of ergosterol (79). The fungistatic effects of FLC 
on fungal cells are primarily attributed to changes in membrane structure and 
function due to ergosterol depletion and the buildup of toxic sterol precursors (80). 
Ergosterol has been shown to be important in V-ATPase activity and 
vacuolar acidification (81). Zhang et al. showed that FLC affects proper V-ATPase 
activity, which could potentially contribute to the inhibitory effects of FLC through 
disruption of multiple downstream cellular processes (81). FLC treatment also 
results in the accumulation of methylated sterols, especially 14-methyl-3,6, diols. 
Deletion strains of C. albicans that are unable to synthesize 14-methyl-3,6 diol 
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have been shown to be resistant to FLC, suggesting that toxic sterol intermediates 
play a role in the antifungal activity of FLC (82). Additional studies in S. cerevisiae 
have shown that the replacement of ergosterol with methylated sterols affects the 
membrane rigidity and fluidity (83). FLC also likely leads to growth inhibition 
through production of endogenous reactive oxygen species (84). Proteomic 
analysis in C. albicans also highlighted the increased abundance of proteins 
associated with cell wall integrity during FLC treatment, suggesting FLC also 
induces cell wall stress (85).  
The effects of FLC have not been specifically investigated in C. neoformans, 
but they are likely similar to the effects described above. Intriguingly, sterol-rich 
domains in fungal plasma membranes, which include ergosterol, may also play a 
key role in cellular polarity and cytokinesis (86). Furthermore, a study in C. albicans 
showed the initial effects of FLC lead to cytokinesis defects, which may contribute 
to the formation of resistant aneuploids (87). In C. neoformans, cells have also 
been shown to confer resistance to FLC through aneuploidy, and it would be of 
particular interest to explore whether the initial effects of FLC on C. neoformans 
cells could potentially lead to cellular growth defects that could lead to resistant 
aneuploids.    
 
Aneuploidy During FLC Treatment in C. neoformans 
The molecular mechanisms underlying how C. neoformans cells evade the effects 
of FLC and become resistant have not been well characterized. In another 
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pathogenic species, Candida, the mechanisms have been more thoroughly 
studied and have been shown to emerge through mutations that result in drug 
target overexpression, drug target modification, sterol synthesis modification, or 
increased drug efflux (88). In addition to mutations, aneuploidy has also been 
shown to produce FLC resistant cells through key gene duplications (89–93).  
In C. neoformans, aneuploid formation is thought to be the primary 
mechanism of FLC resistance. Studies have shown that resistant populations of 
C. neoformans cells exhibit disomy of certain whole chromosomes that are 
beneficial for FLC resistance (57). Disomy of chromosome 1 is typically the first 
duplication seen during FLC resistance, but additional chromosomal duplications 
are associated with higher levels of resistance. Under higher FLC concentrations, 
resistant cells have been shown to contain disomies of up to four chromosomes 
(chromosome 1, 4, 10 and 14) (57). ERG11, the target of FLC, and AFR1, a gene 
that encodes the ATP-binding cassette (ABC) transporter efflux pump, are both 
located on chromosome 1 and have been shown to directly determine FLC 
resistance in C. neoformans (57).  A study investigated the role of ERG11 in 
conferring resistance by inserting a copy of the ERG11 gene onto chromosome 3, 
which resulted in increased FLC resistance without duplication of chromosome 1 
(57). The importance of AFR1 in FLC resistance has been shown through the 
reduced resistance of its deletion strain (57).  
Disomy of chromosome 4 is the second most common disomy observed in 
FLC resistant cells. Three genes important in ER maintenance, SEY1, GLO3, and 
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GSC2, are located on chromosome 4 and have been shown to be important in FLC 
resistance (94). In addition to the genes located on chromosome 4, YOP1, located 
on chromosome 7, is an ER-curvature maintenance protein shown to interact with 
SEY1 and play a role in FLC resistance (94). These ER-associated genes likely 
increase the fitness of cells during FLC treatment by reducing the effects of FLC 
on the ER (94).  
 
Mechanisms of Aneuploid Formation 
The increased fitness of aneuploids observed during FLC exposure is intriguing. 
Aneuploidy is characterized by an imbalanced chromosome state, which is 
generally thought to be detrimental to the fitness of a cell. There are several 
mechanisms to ensure proper cell division and prevent aneuploid formation (95). 
When aneuploidy does arise, it is typically poorly tolerated due to its detrimental 
consequences (57, 96). It has been estimated that aneuploidy only occurs 
approximately once in 5 x 105 cell divisions in yeast (97). Notably, this rate 
increases to approximately 0.3-0.6% in C. neoformans during FLC treatment (57). 
This increase in aneuploidy during drug treatment highlights the potential 
advantage of aneuploidy at a population level as a source of adaptive phenotypic 
change (98). Although aneuploid formation has been shown to be important in 
conferring resistance in C. neoformans, the mechanisms underlying aneuploid 
formation during FLC treatment have not been thoroughly investigated.  
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Although it has not been shown whether aneuploids are produced or 
selected during FLC treatment, aneuploid formation generally involves defects in 
mitosis or cytokinesis, which may arise due to FLC-triggered ergosterol depletion. 
Whole chromosomal aneuploidy typically develops through chromosome 
missegregation after DNA replication. More specifically, it has been shown to arise 
through the following defects:  spindle assembly checkpoint defects, improper 
microtubule-kinetochore attachment, cohesion errors, supernumerary 
centrosomes, tetraploid formation, and telomeric defects (99).  
Interestingly, a recent study in the ascomycete, Candida albicans, showed 
that aneuploidy may arise during FLC treatment through a tetraploid intermediate 
state. It showed that C. albicans cells become aneuploid in response to FLC by 
producing a tetraploid cell, which then undergoes subsequent DNA 
missegregation to form aneuploid cells. A tetraploid cell is formed through a delay 
in budding and a failure in cytokinesis, which produces a three-budded or “trimera” 
cell. Trimeras continue to undergo nuclear division to produce cells with two nuclei. 
Binucleate cells undergo a mitotic collapse followed by successful cell separation 
or cytokinesis, resulting in a tetraploid cell (87). Tetraploidy has previously been 
described to produce aneuploids due to the formation of extra centrosomes, which 
then result in multipolar spindles and subsequent chromosome missegregation 
(99). It is important to note that there are several unique differences in the cell 
cycle of C. albicans compared to C. neoformans. C. neoformans is predominantly 
a haploid, while C. albicans is a diploid yeast. Additionally, as mentioned earlier, 
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C. neoformans undergoes a unique mitosis, whereas C. albicans undergoes a 
closed mitosis similar to other ascomycetes. Lastly, aneuploids that arise during 
FLC treatment in C. neoformans primarily consist of whole chromosome 
duplications, whereas the aneuploidy in C. albicans FLC-resistant cells typically 
refers to the addition of an isochromosome of the left arm of chromosome 5 (91, 
92). Therefore, the process of aneuploid formation during FLC treatment in C. 
neoformans may differ from that described in C. albicans. 
 
FLC Heteroresistance in C. neoformans 
The Kwon-Chung lab has characterized the aneuploid-based resistance to FLC in 
C. neoformans as heteroresistance. Mondon et al. first described the phenomenon 
of FLC heteroresistance in C. neoformans through the characterization of two 
clinical isolates, one from a non-AIDS patient never treated with FLC and one from 
an AIDS patient that exhibited recurrent cryptococcal meningitis (100). This study 
used the term heteroresistance to describe the wide array of susceptibilities seen 
in a clonal population of cells during FLC treatment (100). Additional in vitro and in 
vivo studies showed that heteroresistance is an intrinsic feature of C. neoformans 
that promotes virulence and more thoroughly defined the phenomenon of 
heteroresistance to include three characteristics (Figure 1.2). The first major 
characteristic of heteroresistance is the ability to isolate a homogenous population 
of resistant cells after one sub cloning, while a uniform population of susceptible 
cells cannot be isolated. The second characteristic is the potential of FLC-treated 
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cells to adapt in a step-wise manner to increasing levels of FLC, resulting in higher 
levels of heteroresistance. The last characteristic of heteroresistance is the ability 
of cells that have acquired increased levels of heteroresistance to revert back to 
their original susceptibility and MIC level when passaged several times in drug-
free media (58, 101, Figure 1.2).  
These initial studies on heteroresistance provide a good framework for 
further elucidation of the mechanisms responsible for the development of FLC 
resistance in C. neoformans. Hypothetically, the phenomenon of heteroresistance 
described above is a form of bet hedging, where clonal cells exhibit phenotypic 
heterogeneity that allows for the population to better adapt to stress (102, 103). 
How exactly the differences between individual cells in a clonal population could 
predispose them to become resistant aneuploids during FLC treatment still 
remains elusive.  
 
Phenotypic Heterogeneity in C. neoformans 
Phenotypic or non-genetic heterogeneity refers to the diversity within an isogenic 
population of cells that does not have a genetic basis (104). This underlying 
heterogeneity has been shown to play a critical role in acquisition of drug 
resistance in several microbial pathogens, highlighting the diversity in drug 
response between individual cells that is often overlooked (104, 105). It plays a 
significant role in drug resistance by allowing a subpopulation of cells to grow in 
conditions that are inhibitory to the majority of cells. Increased survival due to 
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phenotypic heterogeneity is typically non-heritable, so it is often referred to as a 
type of transient resistance. A prominent example of transient resistance has been 
described in bacteria as persistence, which arises due to a subpopulation of slow-
growing cells that are able to better survive the stress of the drug (106, 107). 
Although persistence may potentially promote resistance, it differs from resistance 
in the fact that a clonal population of cells exhibiting increased proliferation during 
antibiotic treatment cannot be isolated. Instead, the persistent cells will display the 
same initial heterogeneous response to the antibiotic treatment (106, 107). 
Persistence leads to recurrence, and it has shown to occur in multiple human 
pathogens, including fungi (109). FLC heteroresistance in C. neoformans seems 
to be a chimera between persistence and resistance. During FLC treatment in C. 
neoformans, the isolation of a clonal population of resistant cells is possible, due 
to the fact that aneuploidy is heritable. However, the isolation of a clonal population 
of susceptible cells is not possible, suggesting there is an underlying source of 
phenotypic heterogeneity within the population.  
Phenotypic heterogeneity and its role in FLC heteroresistance has not been 
addressed in C. neoformans. In clonal single-celled organisms, phenotypic 
heterogeneity is largely attributed to gene expression “noise” or differential gene 
expression, which arises during cellular processes, such as the developmental 
processes of cell cycle progression and cellular ageing (110, 111). Cells within a 
clonal population are asynchronous and express different gene profiles dependent 
on their cell cycle stage (112). Additionally, asymmetrical cell division between 
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mother and daughter cells also results in increased diversity, and, interestingly, 
even bacterial cells that undergo symmetrical division have been shown to 
undergo replicative aging (105, 113). Replicative aging leads to unequal 
segregation of cellular components, producing age-dependent heterogeneity 
within a genetically-clonal population (102, 114). The cell cycle stage and cell age 
are two potential sources of phenotypic heterogeneity in C. neoformans that likely 
contribute to the heterogeneous response to FLC. Interestingly, dormant cells that 
appear to be metabolically similar to the previously described persistent cells have 
been shown to occur in in vivo infections of C. neoformans (115, 116). Through 
single-cell flow cytometry analysis, cells isolated from different host niches showed 
a subpopulation of cells thought to be dormant cells due to their low-stress 
response phenotype. How dormant cells of C. neoformans respond to FLC has not 
been investigated. A correlation between replicative age and FLC resistance has 
been previously described in C. neoformans. Bouklas et al. utilized magnetic 
labeling to isolate older populations of cell (cells that had undergone 15 divisions) 
and showed  that older cells exhibit an overall increase in stress resistance, 
including FLC resistance (117). This increased resistance is thought to be due to 
the increase in cell wall size in older cells, which could potentially reduce FLC 
penetration (117). Older cells may also exhibit increased FLC resistance due to 
their increased exposure to reactive oxygen species, which could contribute to 
aneuploid formation (84). It would be of particular interest to see how dormant cells 
and older cells contribute to the heterogeneous response to FLC in C. neoformans. 
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A better understanding of how phenotypic heterogeneity affects FLC 
heteroresistance in C. neoformans could potentially lead to better therapeutic 
approaches to prevent FLC resistance and reoccurrence. In addition to exploring 
the intrinsic sources of phenotypic heterogeneity that potentially lead to FLC 
heteroresistance, a better characterization of the effects of extrinsic sources on 
heteroresistance should also be investigated. Environmental changes contribute 
to overall changes in gene expression which affect drug response. For example, 
temperature growth has shown to affect biofilm susceptibility to antifungals in C. 
neoformans (118). Additional extrinsic factors, such as: nutrient availability, 
population density, and oxidative stress, have all also been shown to promote 
persistence and probably also play a role in FLC heteroresistance (109). 
 
SUMMARY 
In conclusion, C. neoformans is a basidiomycete, human pathogen that is 
commonly treated using FLC. Previous studies have shown that C. neoformans 
cells are able to become resistant to FLC by undergoing aneuploid formation (57, 
58). The mechanisms underlying aneuploid formation during FLC treatment 
remain unknown in C. neoformans. Additionally, FLC is a fungistatic drug that may 
potentially allow for survival of certain cells without acquiring resistance, similar to 
the occurrence of persistence commonly seen in bacterial populations (106-109). 
The research in the following two chapters will investigate the mechanisms of 
fluconazole-based aneuploidy in C. neoformans and characterize the 
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heterogeneous response to FLC on a single cell and colony level. A better 
understanding of the complex response of C. neoformans cells to FLC may 
contribute to improved therapeutic approaches.  
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Figure 1.1. C. neoformans undergoes a unique mitotic cycle compared to 
ascomycetes. 1-9: In non-dividing cells, centromeres are not clustered and are 
positioned at the nuclear periphery. 2-4: Prior to mitosis, centromeres cluster 
concomitant with a step-wise assembly of the kinetochores. 5: C. neoformans 
undergoes a semi-open mitosis and chromatin moves from the mother cell to the 
daughter cell. 6-7: Division occurs and half the chromatin moves back to the 
mother cell. Figure adapted from (4). 
 
 25 
Figure 1.2. C. neoformans cells display heteroresistance to fluconazole. 1: 
The level of heteroresistance refers to the concentration of FLC where the majority 
of cells are susceptible, but a few subpopulations are viable. 2: These 
subpopulations are able to adapt in a step-wise manner to increasing levels of FLC 
concentrations. 3: Cells revert back to their original level of susceptibility when 
passaged into drug-free media. Model adapted from (101). 
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S. c S. p C. n 
(CNAG #) 
E-value U. m. 
(UMAG 
#) 
E-value Function 
in  
S. 
cerevisiae 
Referenc
es 
Tem1 Spg1 05513  3.00E-83 11050  1.00E-78 GTP-
binding 
protein  
U: (Straube, 
Weber et al. 
2005) 
Cdc15 Cdc7 06845 5.00E-58 00721  2.00E-59 protein 
kinase of 
MEN 
 
Mob1 Mob1 05541  9.00E-58 04352 2.00E-64 component 
of MEN 
U: (Sartorel 
and Perez-
Martin 
2012) 
Cdc14 Clp1/
Flp1 
00498  1.00E-83 06187  7.00E-90 protein 
phosphata
se 
 
Sps1 Sid1 03290 6.00E-83 05543  9.00E-80 protein 
serine/thre
onine 
kinase 
U: 
(Sandrock, 
Bohmer et 
al. 2006) 
Dbf2 Sid2 02194  2.00E-
157 
03446  1.00E-151 protein 
serine/thre
onine 
kinase 
 
Myo1 Myo2
Myp2 
01536  0.00E+00 03286  0.00E+00 type II 
myosin 
heavy 
chain 
C: 
(Aboobakar
, Wang et 
al. 2011) 
Mlc1 Cdc4 00808 1.00E-29 11848 3.00E-36 myosin 
light chain 
U: (Bohmer, 
Ripp et al. 
2009) 
Act1 Act1 00483 0.00E+00 11232 0.00E+00 actin   
Iqg1 Rng2 03763  2.00E-24 10730  3.00E-30 IQGAP-
related 
protein 
 
Bni1 Cdc12 04815 7.00E-22 12254  4.00E-32 formin C: (Chang, 
Lamichhan
e et al. 
2012) 
 U: (Freitag, 
Lanver et 
al. 2011) 
Bnr1 Fus1 - - 01141  1.00E-09 formin U: (Freitag, 
Lanver et 
al. 2011) 
Tpm1 Cdc8 05701 3.00E-18 11985  2.00E-21 tropomyosi
n 
C: (Chang, 
Lamichhan
e et al. 
2012)  
Tpm2 Cdc8 05701  2.00E-16 11985  6.00E-24 tropomyosi
n 
 
Pfy1 Cdc3 00584  1.00E-24 10832  4.00E-32 profilin  
Cdc42 Cdc42 05348  1.00E-
117 
00295  2.00E-122 small rho-
like 
GTPase 
C: (Ballou, 
Nichols et 
al. 2009) 
 27 
 U: 
(Bohmer, 
Bohmer et 
al. 2008) 
Bud4 Mid2 06902  2.00E-08 UMAG12
265 
1.00E-56* anillin-like 
protein 
 
Hof1 Cdc15
, Imp2 
06740  6.00E-12 00168  8.00E-09 F-bar 
protein 
 
Bni5 - 01051  3.40E+00 - - septin-
Myo1 
linker 
 
Chs1 Chs1 07499 0.00E+00 10117  0.00E+00 chitin 
synthase 
C: (Banks, 
Specht et 
al. 2005) 
 U: (Weber, 
Assmann et 
al. 2006) 
 
Chs2 Chs2 03326 0.00E+00 04290  0.00E+00 chitin 
synthase 
Chs3 - 05581  0.00E+00 10277  0.00E+00 chitin 
synthase 
Chs4 Cfh1 07636  9.00E-83 10641 1.00E-69 activator of 
Chs3p 
 
Fks1 
(Gsc1
) 
Bgs4 06508  0.00E+00 01639  0.00E+00 subunit of 
1,3-beta-D-
glucan 
synthase 
 
Fks2 
(Gsc2
) 
Bgs4 06508 0.00E+00 01639 0.00E+00 subunit of 
1,3-beta-D-
glucan 
synthase 
 
Rho1 Rho5 03315  3.00E-
102 
05734  8.00E-107 GTP-
binding 
protein  
 
Myo2 Myo5
2 
06971 0.00E+00 04555  0.00E+00 type V 
myosin 
heavy 
chain  
U: (Weber, 
Gruber et 
al. 2003) 
Inn1 Fic1 03422  3.00E-04 06398 8.00E-47* C2 domain 
protein 
C: 
(Aboobakar
, Wang et 
al. 2011) 
Cyk3 Cyk3 - - - - SH3 
domain 
protein 
 
Cbk1 Orb6 03567  0.00E+00 04956  
 
0.00E+00 protein 
serine/thre
onine 
kinase of 
RAM 
U: (Sartorel 
and Perez-
Martin 
2012) 
C: (Walton, 
Heitman et 
al. 2006) 
Ssd1 Sts5 03345  1.00E-
129 
01220  1.00E-158 translation
al 
repressor 
 
Mob2 Mob2 05794 4.00E-66 12135  
 
1.00E-62 activator of 
Cbk1p 
kinase in 
RAM 
U: (Sartorel 
and Perez-
Martin 
2012) 
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Kic1 Nak1 00405  5.00E-83 11396  2.00E-96 protein 
kinase of 
the 
PAK/Ste20 
family 
C: (Walton, 
Heitman et 
al. 2006) 
Tao3 Mor2 03622  2.00E-
147 
10098  1.00E-154 RAM 
component 
Sog2 Sog2 03918  7.00E-14 02656  1.00E-15 RAM 
component 
Cdc3 Spn1 05925  3.00E-
146 
10503  5.00E-150 septin C: 
(Kozubows
ki and 
Heitman 
2009) 
U: (Alvarez-
Tabares 
and Perez-
Martin 
2010) 
 
Cdc10 Spn2 01373  4.00E-
135 
10644  4.00E-122 septin 
Cdc11 Spn3 02196  5.00E-
112 
03449  2.00E-104 septin 
Cdc12 Spn6 01740  3.00E-
141 
03599  4.00E-152 septin 
Exo84 Exo84 04339  3.00E-24 04147  9.00E-20 exocyst 
complex 
component 
 
Eng1 
(Dse4
) 
Eng2 - - - - daughter 
cell-
specific 
secreted 
protein 
 
 
• The E-value based on similarity to the C. neoformans homologue. 
• References refer to either C. neoformans (marked as C:) or U. maydis (U:)  
 
Table 1.1. List of homologues in cytokinesis C. neoformans var. grubii H99 
(C.n.), U. maydis 521 (U.m.), and S. pombe 972h (S.p.) genomes were probed for 
similarity against S. cerevisiae S288c (S.c.) using FungiDB 
(http://fungidb.org/fungidb/). Recorded E-values were products of protein BLAST 
results from FungiDB. Function and protein sequences were retrieved from SGD 
(http://www.yeastgenome.org). Taken from Altamirano, S, Chandrasekaran, S., 
Kozubowski, L. 2017. Mechanisms of Cytokinesis in Basidiomycetous Yeasts. 
Fungal Biol Rev 2:73—87. 
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ABSTRACT 
Cryptococcus neoformans is a pathogenic yeast that causes lethal 
cryptococcal meningitis in immunocompromised patients. One of the challenges in 
treating cryptococcosis is the development of resistance to azole antifungals. 
Previous studies linked azole resistance to elevated copies of critical resistance 
genes in aneuploid cells. However, how aneuploidy is formed in the presence of 
azole drugs remains unclear. This study found that treatment with inhibitory 
concentrations of an azole drug, fluconazole (FLC), led to a significant population 
of cells with increased DNA content, through the following defects: inhibition of 
budding, premature mitosis, and inhibition of cytokinesis followed by replication in 
the mother cell.  Inhibition and/or a delay in cytokinesis led to the formation of cells 
with more than one daughter attached (multimeric cells). To investigate which part 
of cytokinesis fails in the presence of FLC, the dynamics of the actomyosin ring 
(AMR), septins, and Cts1, a protein involved in cell separation, were analyzed with 
time-lapse microscopy. Following the constriction of the AMR, septins assembled, 
and the septum was formed between the mother and daughter cells. However, a 
final degradation of the septum was affected. Enlarged cells with aberrant 
morphology including multimeric cells exhibited increased potential to proliferate 
in the presence of FLC. These findings suggest that pleiotropic effects of FLC on 
growth and mitotic division lead to an increase in DNA content resulting in cells 
less sensitive to the drug. Cells with increased DNA content continue to proliferate 
and therefore increase the chance of forming resistant populations.  
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INTRODUCTION 
Genomic integrity is a crucial attribute of all living forms yet in some 
circumstances transient abnormalities in chromosomal number and composition 
are beneficial for the cell population (3, 4). For instance, development of 
aneuploidy is a common survival mechanism for cells under selective pressure of 
adverse environmental conditions (4). Aneuploidy is typical for malignant cells that 
strive to proliferate despite nutrient limitation and inhibitory effects of anticancer 
drugs (5). Aneuploidy occurs frequently in pathogenic organisms that encounter 
harsh inhibitory conditions within the host and battle against therapeutic regimens; 
prominent examples include the protozoan Leishmania, an ascomycetous yeast 
Candida albicans and a basidiomycetous yeast Cryptococcus neoformans, the 
most common causal agent of fungal meningitis in AIDS and transplant patients 
(1, 6-9). How can changes in chromosomal composition lead to an improved 
survival? The key to this process is the selection favoring cells with elevated copies 
of specific genes that provide growth advantage in particular inhibitory conditions. 
In most cases retention of an entire additional chromosome or addition of an arm 
of a specific chromosome occurs in selected population of cells. Importantly, the 
environmental inhibitory effects not only select for organisms with specifically 
altered chromosomal composition, those effects often induce genomic changes by 
mechanisms that remain ill-defined (3). The resulting pool of cells with various 
karyotypes increases the chances of survival; individuals with beneficial 
chromosomal compositions are selectively favored under the inhibitory pressure 
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(3). Prominent examples of fungal pathogens developing resistance to azole 
antifungal treatments are those observed in C. albicans and C. neoformans. The 
fungistatic azole drug fluconazole (FLC) targets lanosterol 14α-demethylase, 
Erg11, which is responsible for converting lanosterol to ergosterol in the ergosterol 
biosynthesis pathway (10). Ergosterol is known to be an essential component for 
cell membrane permeability and fluidity, but the exact inhibitory consequences of 
ergosterol diminishment remain elusive (11).  
Specific genes that confer resistance to FLC and thus determine the 
selection of a particular chromosomal configuration in C. albicans and C. 
neoformans are well established (1, 8). On the other hand, mechanisms through 
which FLC potentially leads to changes in chromosomal composition in these 
human pathogens of significance remain poorly characterized. In a diploid yeast, 
C. albicans, treatment with FLC leads to growth inhibition, premature nuclear and 
spindle cycles, and a failure in cytokinesis resulting in a formation of multimeric 
cells containing tetraploid nuclei (12). Tetraploid cells give raise to aneuploid 
populations of which most fit individuals are selected under the FLC inhibitory 
pressure and lead to FLC resistance (12). The exact mechanism through which 
FLC inhibits cytokinesis in C. albicans remains unknown.  
It is well established that the in vitro FLC-triggered drug resistance in C. 
neoformans called heteroresistance is a relatively rare occurrence and is based 
primarily on the formation of aneuploids (<1% of the FLC-treated population) (9). 
However, the initial effects of FLC on the population of C. neoformans have not 
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been characterized and the mechanisms by which FLC triggers changes in 
chromosome number in C. neoformans remain unclear. Recent studies reveal 
several differences in mitosis between C. neoformans and S. cerevisiae, which 
may suggest that FLC dependent aneuploidy formation in C. neoformans may 
differ from previously described mechanisms in hemiascomycetous yeasts 
including C. albicans (13). 
Here we investigated mechanisms through which FLC affects ploidy in C. 
neoformans. Our data suggest that exposure to inhibitory concentrations of FLC 
leads to a progressive diminishment of the ability to initiate budding and 
subsequent growth while permitting nuclear events. In addition, FLC inhibits 
cytokinesis, most likely by imposing a delay or a permanent block in the 
degradation of the primary septum. The resulting populations of cells with an 
increase in DNA content grow better under the inhibitory concentration of FLC, 
hypothetically increasing the chance of forming aneuploids out of which the most 
adapted cells are selected giving rise to fully resistant populations. 
 
RESULTS 
FLC treatment results in an increase in DNA content in a significant fraction 
of cells.  
At the concentration of FLC that is equal to the heteroresistance level, resistant 
colonies are aneuploids, initially with disomic chromosome 1 (9). FLC could 
potentially act solely as a selection agent to allow growth of only a small fraction 
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of pre-existing aneuploids that may be naturally present in a population. 
Alternatively, FLC may act as a driving force, stimulating the formation of 
aneuploids from which a small proportion is selected for proliferation under the 
inhibitory concentration of the drug, similarly to the recently proposed mechanism 
in C. albicans and as hypothesized in studies that involved C. neoformans (9, 12). 
Based on the fact that C. neoformans is predominantly haploid, development of 
aneuploidy could proceed through formation of diploid cells, analogous to the 
aneuploid formation based on a tetraploid intermediate described for C. albicans 
(12). To test if FLC has an effect on DNA content of C. neoformans during initial 
exposure to the drug, cells treated with FLC were fixed, stained with propidium 
iodide (PI), and examined using fluorescence flow cytometry. Strikingly, treatment 
of cells with 32 µg/ml FLC at 24°C for 12 and 14 hours resulted in 20% and 88%, 
respectively, of the cell population with ploidy levels at or above 4n (Figure 2.1). 
The significant increase of the cell number with ploidy level at or above 4n between 
12 and 14 hours (Figure 2.1) was not consistent from experiment to experiment as 
in some cases maximum ploidy was present at around 9 hours with no significant 
further change in later time points (data not shown). The longest incubation time 
tested was 18 hours, which did not show further significant increase in ploidy level 
(data not shown). The maximum ploidy level in a significant population of cells 
observed at any of the test conditions was approximately 4n, although a smaller 
fraction of cells with ploidy levels beyond 4n was also present at inhibitory 
concentrations of FLC (Figure 2.1). The fraction of cells with increased DNA 
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content was proportional to the concentration of FLC. Altogether, these data 
suggest that FLC treatment at inhibitory concentrations leads to an increase in 
ploidy beyond 2n.  
 
Treatment with FLC causes inhibition of budding. 
We tested whether FLC treatment resulted in any of the following cellular defects 
that may individually or collectively result in increased DNA content: 1.  Inhibition 
of growth coupled with re-replication. 2. A defect in cytokinesis. 3. Unequal 
chromosomal segregation during mitosis. 
The inhibitory effect of FLC, similar to other azole antifungals, has been 
associated with the depletion of ergosterol from the plasma membrane (14). The 
minimum level of ergosterol needed to sustain cellular growth is not clear. Doubling 
time of C. neoformans under unperturbed growth conditions in the laboratory is 
approximately 2 hours (15). Therefore, during the initial period of FLC treatment, 
we expect the growth of cells to be relatively normal, as the depletion of ergosterol 
from the membranes may take more than a doubling time. Consistent with this 
prediction, we found that treatment of cells with 32 µg/ml FLC for 3 hours resulted 
in only ~20% reduction in new bud formation relative to the control (Figure 2.2). 
However, treatment for 6 hours resulted in a more significant inhibition of budding 
(~50% reduction as compared to the control, Figure 2.2). These data suggest that 
the effect of FLC on growth is delayed, presumably due to the relatively slow 
exchange rate of ergosterol within the plasma membrane. If this were the case, we 
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would expect that further slowdown in the exchange rate may lead to even longer 
delay in the effect of FLC on bud initiation. Consistent with this possibility, the 
addition of actin depolymerizing agent latrunculin B (LatB) during the pretreatment 
of unbudded cells with FLC leads to a further delay in time needed to significantly 
inhibit bud initiation; the effective inhibition by FLC when combined with the LatB 
was achieved by 14 hours (Figure 2.3). Cells treated with LatB for 18 hours initiated 
budding when released into drug free media indicated that prolonged exposure to 
LatB did not have any significant adverse permanent effects on cell growth (Figure 
2.3). Taken together, these data suggest that FLC treatment leads to inhibition of 
bud initiation and subsequent growth. However, the effect is delayed. We 
speculate that levels of plasma membrane ergosterol reach a critical minimum 
after longer incubation with FLC, resulting in significant inhibitions in the initiation 
of budding and further bud growth. 
 
FLC treatment leads to a defect in cytokinesis.  
Hypothetically, the fraction of cells with increased DNA content may result from a 
debilitating effect of FLC on cytokinesis. To test this hypothesis, we assessed the 
morphology of FLC-treated cells. To differentiate between cells with normal and 
increased DNA content, we fixed the cells, stained the DNA with PI, and 
subsequently fractionated using a FACS (fluorescence assisted cell sorting) 
instrument. Fractions of cells with increased ploidy were collected, and the 
morphology was scored under the microscope. Cells with ploidy level close to 1n 
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were predominantly unbudded or contained a single usually small bud (Figure 2.4). 
Fractions with higher ploidy were enriched in cells characterized by the presence 
of more than one daughter cell (multimeric cells). These multimeric cells were 
either trimeras, with two daughter cells born from the mother cell, or contained an 
additional daughter (a granddaughter) born from one of the daughters (Figure 2.4). 
The fraction with ploidy above 4n contained ~44% of multimeric cells. These 
results suggest that treatment with FLC leads to failure in cytokinesis. To rule out 
the possibility that multimeric cells result from cell fusion events, we mixed two 
strains, one that expressed histone H4 tagged with GFP and the other expressing 
H4 tagged with mCherry and subjected the mixed cell culture to FLC. While 
multimeric cells expressing either of the two fluorescent chimeras were frequent 
after longer incubations with FLC, we could not find multimeric cells that expressed 
both GFP and mCherry (data not shown). This is consistent with our expectation 
that multimeric cells are a result of cell division failure rather than cell fusion events.  
 
FLC treatment leads to uncoupling of growth from the cell cycle. 
Interestingly the fraction of cells with the highest ploidy also contained significant 
amount of cells with a single bud (45%) and unbudded cells (11%) suggesting that 
re-replication has taken place as a result of FLC treatment (Figure 2.4). A delay or 
complete block in cell separation during FLC treatment potentially leads to an 
increase in DNA content in unseparated cells if the cell cycle continues and results 
in subsequent rounds of replication. We tested this hypothesis further by subjecting 
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a population of pre-selected unbudded cells to FLC and assessing DNA content 
based on PI fluorescence using flow cytometry. Importantly, we examined cells 
after 3 and 6 hours of treatment with 32 µg/ml FLC, which are times when no 
multimeric cells are detected in the population. Strikingly, after 6 hours of FLC 
treatment ~50% of cells indicated DNA content above 2n, with a predominant 
population (visible as a peak) that corresponded to cells with 3n DNA content 
(Figure 2.5A). These results suggest that upon FLC treatment, cells exhibit a 
failure or a delay in cytokinesis with a concomitant new round of replication in the 
mother cell. An alternative, non-exclusive possibility is that FLC treatment may 
result in a failure to transition the chromatin to the daughter cell prior to metaphase, 
an event that normally occurs in C. neoformans (13). Hypothetically, failure to 
translocate the chromatin to the daughter cell may be followed by spindle formation 
and subsequent nuclear division in the mother cell leading to increased ploidy. To 
address this possibility, we analyzed the localization of the mitotic spindle in cells 
treated with 32 µg/ml FLC for 22 hours, based on a strain that expressed GFP-
tagged ß-tubulin. Consistent with previous studies, in the control sample the 
spindle was detected exclusively within daughter cells (Figure 2.5B). In contrast, ~ 
16% (n = 33) of FLC-treated cells that had a detectable spindle were either 
unbudded or contained extremely small buds and the spindle was positioned within 
the mother cell (Figure 5B). Consistently, we found that when the spindle was 
visible, the size of the daughter cells in the control was relatively uniform (𝑥 =	3.2, 
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SD = 0.31). However, the FLC-treated cells exhibited a broader range of sizes of 
daughter cells when spindle was detected (𝑥 =	3.5, SD = 0.84 µm) (Figure 2.5C).  
To further assess the uncoupling of growth from the mitotic cycle, we 
monitored clustering of centromeres in FLC treated cells.  In C. neoformans, 
centromeres are not clustered in interphase cells and cells with small buds, but 
they cluster in medium budded cells in preparation for mitosis (13). To visualize 
centromeres, we utilized a strain that expressed a centromeric histone variant 
Cse4 expressed from an endogenous promoter and tagged with mCherry and a 
component of the nuclear envelope, Ndc1, tagged with GFP. Strikingly, when cells 
were treated with 32 µg/ml FLC for 13 and 15 hours, 50% and 35% of unbudded 
cells, respectively, had already clustered centromeres (Figure 2.6, panel 3). In 
addition, 3% (13 hours, n = 65) and 9% (15 hours, n = 75) of budded cells 
contained 2 nuclei in the mother cell (Figure 6, panel 3). Moreover, 3% (13 hours, 
n = 65) and 4% (15 hours, n = 75) of budded cells showed some centromeres in 
the bud neck area (Figure 2.6, panels 1 and 4). Occasionally, we also observed 
cells with a portion of centromeres that localized outside of the nuclear area 
marked by the Ndc1 (Figure 2.6, panels 2 and 5). These data suggest that upon 
treatment with FLC, the mitotic cycle is less inhibited as compared to growth and 
budding. This leads to clustering of centromeres, spindle assembly, and nuclear 
division in the mother cell, resulting in cells with increased DNA content and 
potentially aberrant chromosomal composition.  
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Analysis of the mitotic defects resulting from FLC treatment.  
We investigated what specific defects accounted for the inability of cells to 
separate during FLC treatment. Defects in cell separation in basidiomycetous 
yeasts may result from a lack of actomyosin ring (AMR) constriction, failure in 
septum deposition, or inadequate degradation of the primary septum toward the 
end of cytokinesis (16). To monitor constriction of the AMR, we performed time-
lapse microscopy based on a strain of C. neoformans that expressed a component 
of the AMR, myosin heavy chain, Myo1, tagged with mCherry and a nucleoporin, 
Nup107, tagged with GFP (to monitor the stage of mitosis). Cells with single 
daughters in both the control and FLC treated samples, exhibited normal AMR 
constriction (Figure 2.8A and data not shown). However, FLC-treated cells with 
only a single daughter may be already partially resistant to FLC. Therefore, we 
focused on multimeric cells, as they represented the fraction of cells for which cell 
separation has failed. In all examined multimeras (n = 7), AMR constricted between 
the mother cell and the daughters (Figure 2.8A; Figure 2.7). Interestingly, the 
dynamics of the constriction varied significantly as compared to control cells. 
Specifically, while the time of constriction for the DMSO-treated control was 
estimated to take between 10 to 25 minutes (n = 9), assessed times of constriction 
in 5 multimeras that resulted from FLC treatment were 10, 20, 30, 35, and 50 
minutes. Our results indicate that FLC does not inhibit AMR assembly, but FLC 
does cause a delay in AMR constriction.  
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Septin proteins in C. neoformans are essential for cytokinesis under stress 
conditions (17). Therefore, incomplete cytokinesis upon FLC treatment may stem 
from the inability of cells to assemble a robust septin complex at the site of 
cytokinesis. However, we did not observe marked defects in septin localization or 
organization upon FLC treatment (Figure 2.8B). The septins, Cdc3 and Cdc12, are 
essential for the assembly of the septin complex at the mother-bud neck, yet 
cdc3∆or cdc12∆ mutant strains exhibit largely normal cytokinesis in non-stress 
conditions (24°C), albeit having partially abnormal primary septa (17).  Strikingly, 
cdc3∆and cdc12∆ strains exhibited hypersensitivity to FLC with a clear defect in 
cytokinesis at 24°C (Figure 2.8C, D). Synthetic interaction between septin 
deletions and FLC further suggests that FLC-mediated inhibition of cytokinesis is 
not directly related to septin function.   
Calcineurin high temperature suppressor 1, Cts1, has been implicated in 
the cell separation pathway in C. neoformans. Cts1 is thought to contribute to the 
primary septum formation (18). GFP-Cts1 localizes to the mother-bud neck and 
follows the constriction of the AMR during cytokinesis (19). FLC treatment did not 
affect localization and dynamics of GFP-Cts1, a finding consistent with the septum 
being formed during FLC treatment (Figure 2.9A and B).  
To assess septum formation, we stained FLC-treated cells with calcofluor 
white to visualize chitin deposition. We noted that in the control cells, the calcofluor 
fluorescence was visible at the mother bud neck in small, medium, and large 
budded cells (data not shown). This implies that chitin may be deposited at the bud 
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neck prior to mitosis in addition to the primary septum formation, similar to S. 
cerevisiae (20). Importantly, we did not find a significant diminishment of the 
calcofluor fluorescence at the mother-bud neck of cells treated with FLC including 
the multimeric cells, indicating that FLC does not prevent septum formation (Figure 
2.9C). In support of this conclusion, we observed a dark line at the bud neck 
between the mother and the daughters in the trimeric cells when imaged in the 
bright field (Figure 2.8; Figure 2.7). In addition, cytoplasm between the mother and 
the daughter cells was discontinuous in multimeric cells when the dark line became 
visible at the mother-bud neck (Figure 2.7B, C) 
Taken together, our data suggest that FLC inhibits final separation of cells 
undergoing cytokinesis, but this defect is not resulting from a lack of AMR 
constriction or septum formation or lack of Cts1 localization and constriction. 
Instead, the defect is in the failure of the final degradation of the primary septum.  
 
Chromosomal loss is not the predominant mechanism responsible for 
generating FLC-resistant cells. 
Harrison et al. have proposed that a diploid C. albicans becomes aneuploid under 
FLC treatment through generation of an intermediate tetraploid stage (12). 
Extrapolating from this scenario, we could envision a haploid C. neoformans 
becoming a diploid in the presence of FLC, which subsequently becomes an 
aneuploid through concerted loss of chromosomes. Hypothetically, a diploid strain 
of C. neoformans would possess a much higher potential to become aneuploid by 
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FLC triggered chromosomal loss and, therefore, the likelihood of a diploid to 
become resistant to FLC should be higher. To test this hypothesis, we artificially 
generated a diploid C. neoformans strain and compared it to two parent haploid 
strains with respect to early response to FLC and the ability to form FLC-resistant 
colonies. When grown on 32 µg/ml of FLC media, the diploid produced visible 
colonies after 72 hours whereas the two haploid parent strains produced no visible 
colonies at that time (data not shown).  However, diploid cells grown in the 
presence of FLC reached an octoploid (8n) state after 14 hours in an analogous 
way to the DNA increase observed in the haploid strain (Figure 2.10).  
Morphological examination of the diploid cells grown in FLC showed multibudded 
cells, indicative of cytokinesis failure, similar to that observed in haploid cells (data 
not shown). These findings imply that diploid C. neoformans cells, while potentially 
less sensitive to FLC as compared to haploids, in an analogous way to the haploid 
cells, fail to undergo cytokinesis and double the ploidy level upon FLC treatment. 
This suggests that chromosomal loss is not sufficient and not the predominant 
mechanism of aneuploidy formation in response to FLC. Furthermore, these data 
indicate that a diploid state is not sufficient to render cells resistant to a 
concentration of FLC that is inhibitory to the isogenic haploid.  
 
FLC treatment leads to unequal distribution of chromatin between the 
mother and the daughter cells.  
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We utilized a strain of C. neoformans that expressed histone H4 tagged with 
mCherry as a proxy to estimate distribution of chromatin during mitosis in cells 
treated with FLC. The strain expressing H4-mCherry exhibited similar sensitivity to 
FLC as the wild type strain, indicating that introducing the mCherry to the C 
terminus of the histone H4 did not change the way FLC affected cell division (data 
not shown). In DMSO-treated control cells, the chromatin was equally distributed 
between the daughter and the mother cell, as the ratio of the H4-mCherry 
fluorescence between the daughter and mother cells was nearly 1 (𝑥 = 1.13, SD: 
028, n = 19). In contrast, some multimeric cells that were treated with FLC 
exhibited markedly unequal distributions of the H4-mCherry signal between the 
mother and the daughter cells (Figure 2.11). Interestingly, there was no 
consistency as to whether more H4-mCherry signal was in the mother or in any of 
the daughters; although, the predominant fraction of multimeras contained 
relatively more chromatin in the mother than in either of the daughters (Figure 
2.11). These data suggest that FLC treatment results in aberrant chromosomal 
distribution leading to cells with relatively higher chromatin content.  
 
FLC-treated cells that are enlarged and/or fail to separate are less sensitive 
to FLC 
Our data suggest that FLC has a pleiotropic effect on cell growth, including 
inhibition of budding, cell separation, and mis-segregation of chromatin during 
mitosis. Collectively, these effects result in cells that are increased in size, have 
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higher DNA content, and are multibudded. Indeed, based on fluorescence 
microscopy profile of the cells treated with 32 µg/ml FLC for 14 hours, we found a 
significant correlation between the cell size and complexity and the DNA content 
(Figure 2.1 and data not shown). We hypothesized that enlarged cells are less 
sensitive to FLC. To test this, cells that were treated with 32 µg/ml FLC for 14 hours 
were fractionated using FACS based on the size and complexity of their 
morphology. Two fractions were collected, one with relatively small cells that were 
either unbudded or contained a single bud, and a second fraction that contained 
unbudded or budded cells that were enlarged or multimeric (Figure 2.12). A third 
(control) sample consisted of cells that were not fractionated, yet were processed 
the same way including passing through the FACS sorter. All three samples were 
plated on media containing 32 µg/ml of FLC and incubated at 24°C. Significantly, 
the fraction of cells containing multimeras exhibited relatively higher resistance to 
FLC as compared to the “small” cell fraction (Figure 2.12). Cells that were not 
subject to fractionation exhibited an intermediate ability to grow in the presence of 
FLC as compared to the other two samples. These findings indicate that cells that 
are enlarged and/or have changed morphologically upon treatment with FLC, 
possess a higher potential to grow in the presence of the drug.  
These findings (Figure 2.12) coupled with our initial FACS data showing the 
morphology of cells with increased DNA content (Figure 2.4) highlight the role of 
multimeric cells as a contributing factor to the increase in ploidy and subsequent 
survival in the presence of FLC. Additionally, it also emphasizes enlarged, 
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unbudded cells as another potential factor contributing to survival. In order to better 
understand the role of enlarged morphology, cells were streaked in the middle of 
a plate containing 24 µg/ml FLC medium.  After 9 hours, before the emergence of 
multimeras, 20 enlarged unbudded or budded cells were picked using a 
micromanipulator and placed on the same plate in known spots. 20 normal sized 
cells were also placed as controls. Six out of 20 of the enlarged cells progressed 
into colonies, while 0 out of 20 of the normal sized controls grew. These data are 
not surprising; the cells that showed an increase in survival were able to grow or 
enlarge during the initial insult of FLC, whereas the non-survivors were unable to 
handle the stress imposed by FLC. The microcolonies formed by the six enlarged 
cells at 24 hours were dissected and the morphology and subsequent mitotic 
divisions were monitored for the succeeding 24 hours. Cells that were already 
multimeras by 24 h exhibited the greatest chance for survival in the presence of 
FLC (formed microcolonies); ~89% of multimeras underwent further growth (Figure 
2.13). In contrast, ~50% of budded cells and ~30% of unbudded cells formed 
microcolonies. The heterogeneity of the population to FLC is intriguing. It will be of 
interest to further explore the basis and the importance of the heterogeneity of the 
initial response to FLC. 
 
DISCUSSION 
Our data suggest that FLC results in an increase in the DNA content in a 
significant fraction of cells, but the effect is delayed. What is most likely to account 
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for the delay is the rate at which ergosterol is depleted in individual cells, however 
other reasons cannot be excluded. For instance, a relatively slow accumulation of 
a toxic byproduct of the FLC-mediated inhibition of ergosterol synthesis may also 
be responsible for the delay (11). Significant inhibition of budding when cells are 
treated with 32 µg/mL of FLC occurs at 6 hours, a time when no significant increase 
of DNA content is yet observed in a heterogeneous population. However, it only 
required ~3 hours for a significant population of cells corresponding to 3n to appear 
when the initial population was composed of unbudded cells. Thus, an initial 
increase in DNA content is likely to occur due to a lack of cell separation coupled 
with subsequent replication in the mother cell. 
FLC inhibits cytokinesis in C. albicans, but the actual mechanism of 
cytokinesis failure has not been explored (12). While we also find that FLC causes 
inhibition of cell separation in C. neoformans, two main differences as compared 
to C. albicans are apparent. First, the C. albicans multimeric cells resulting from 
FLC treatment consist of mother cell and the daughters that remain connected via 
common cytoplasm (12). The authors speculate that the cytoplasmic signaling 
connection between individual cells within the multimera is important for the 
formation of the tetraploid intermediate (12). In contrast, we observe that 
multimeric C. neoformans cells are formed based on a failure of the final cell 
separation despite septa being formed. Therefore, the mother cell and the first 
daughter do not share a common cytoplasm when the second daughter is formed, 
which is consistent with images of multimeras with the discontinuous fluorescent 
 59 
cytoplasmic signal between the attached cells (Figure 2.7). A second clear 
distinction is that the multimeric cells in C. albicans are chains of cells resulting 
from growth of the second daughter cell (a granddaughter) out of the first daughter 
cell, while in C. neoformans, both daughter cells grow consecutively from a single 
mother. We speculate that retention of the cytoplasmic connection in C. albicans 
and a lack thereof in C. neoformans account for this difference. Specifically, in C. 
albicans, cell cycle signaling that normally triggers the next round of budding in the 
mother is acting within the first daughter, which results in a granddaughter. In C. 
neoformans, the mother cell of the multimera is isolated from the unattached 
daughter and the signaling triggers second bud formation within the mother. 
Indeed, we observe multimeras with two daughters attached to the mother and a 
single granddaughter, indicating a later time at which one of the daughters is 
“ready” to initiate budding (Figure 2.4, purple arrow). It is interesting that in C. 
neoformans FLC treatment does not prevent septation in contrast to C. albicans. 
This may indicate that either the physical process of AMR constriction and/or 
septum formation differ in these species, or alternatively, the differences in 
signaling that triggers these events account for various effects of FLC in these 
species. Given that both species produce aneuploid progeny presumably based 
on multimeric cells, the question remains whether aneuploidy formation proceeds 
through distinct mechanisms in these unrelated yeasts. Alternatively, at least in C. 
neoformans, these multimeric cells may not constitute a critical prerequisite to truly 
resistant aneuploids, but rather a byproduct of FLC inhibition that nonetheless 
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increases the survival of cells in the presence of the drug. Answering these 
questions will require further investigation. 
Fernandez C. et al. has demonstrated that mammalian equivalent of 
ergosterol, cholesterol, is required for cytokinesis in human HL-60 cell line and that 
sustained cholesterol starvation leads to the formation of polyploid, multinucleated 
cells with mitotic aberrations (21). The authors hypothesize that cell cycle 
perturbations and polyploidization observed in cholesterol-deficient cells are due 
to reduced Cdk1 activity. Furthermore, affected cells were able to partially traverse 
mitosis and to re-replicate DNA, which led to polyploidy (21). Thus, it is likely that 
the cell separation defect that we observed in C. neoformans is due to depletion 
of ergosterol. Our data suggest that FLC prevents cell separation in C. neoformans 
most likely via inhibition of the final degradation of the primary septum, as the 
primary septum was formed and the two other main events of cytokinesis, AMR 
constriction and septin assembly were not largely affected.  Surprisingly, none of 
the endochitinases encoded by the C. neoformans genome are necessary for the 
final cell separation (22, 23). C. neoformans may not have an enzyme that 
specifically hydrolyzes chitosan, a constituent of the primary septum. Therefore, 
daughter cell separation may proceed based on the increased flexibility and 
solubility of the chitosan (22). It is plausible that FLC disrupts the relative content 
of chitosan leading to defects in cell separation. Alternatively, a delay in AMR 
constriction or other indirect effects of FLC may cause an interruption of a 
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conserved RAM (regulation of Ace2 and morphogenesis) pathway that signals final 
cell separation (24).  
Several abnormal morphologies resulting from FLC treatment reflect its 
diverse effects on cell physiology. We propose that the variability in morphological 
defects result from the heterogeneity that exists in the population of cells that is 
initially exposed to the drug. In its simplest form, the heterogeneity may reflect cells 
that are at various stages of the cell cycle when they are initially exposed to the 
drug (Figure 2.14A). FLC leads to a gradual depletion of ergosterol and 
accumulation of toxic metabolic products. Consequently, cells will be affected in 
various ways depending on when ergosterol levels reach the critical minimum with 
respect to the stage of the cell cycle (Figure 2.14A). Interestingly, populations of 
cells exposed to FLC exhibit variability in the initial response to the drug (Figure 
2.13). It will be of interest to investigate the basis for this heterogeneous response. 
Cells that fail to separate, yet undergo DNA replication and subsequent 
initiation of budding and then proceed through additional rounds of mitosis 
(multimeric cells), are most likely a major group that accounts for the increased 
DNA content as detected via PI staining and flow cytometry (Figure 2.14B). The 
fact that the mother cells undergo replication despite the failure in daughter cell 
separation is consistent with previous findings demonstrating that timing of 
replication in C. neoformans is flexible with respect to timing of the bud initiation 
(15). Therefore, we speculate that inhibition of cell separation by FLC may be 
sufficient to result in next round of replication in those mother cells.   Consistent 
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with multimeras contributing to the fraction of cells with increased ploidy as 
detected by flow cytometry, we find multimeric cells with increased and unequally 
distributed chromatin as judged by the fluorescence of H4-mCherry. Presently, the 
mechanism through which FLC leads to unequal distribution of histone H4 is 
unclear. This defect is likely associated with missegregation of chromosomes, as 
we also observe aberrant segregation of centromeres between mother and 
daughter cells (Figure 2.6). In S. cerevisiae, increase in ploidy is associated with 
chromosomal instability (25, 26). Hypothetically, missegregation of chromosomes 
may be a direct mechanism through which aneuploids are derived. A non-exclusive 
alternative is that cells with increased ploidy may undergo stepwise chromosomal 
loss leading to aneuploidy. FLC causes inhibition of budding, which when coupled 
with subsequent replication would lead to an increase in DNA content. In addition, 
we observe premature mitosis occurring within mother cells, which is consistent 
with unbudded cells present in the fraction with increased ploidy. Thus, FLC leads 
to an increase in DNA content by affecting cellular growth and division via multiple 
mechanisms. The central question is whether cells with increased DNA content 
that are formed in the presence of FLC give rise to a population of aneuploids that 
increases the chance for producing resistant populations. Our study shows that 
cells with increased size and aberrant morphology grow better in the presence of 
FLC consistent with this possibility.  
While increased ploidy due to FLC treatment may not be sufficient to 
generate truly resistant aneuploids in the host, cells with increased DNA content 
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may increase the chance for survival in the presence of the drug and hypothetically 
lead to more persistent infections. Recent studies showed a C. neoformans 
morphological variant with vastly increased ploidy and size called the titan cell (27).  
Titan cells are found during infection and are more resistant to stress and FLC. 
Additionally, they produce populations of more resistant aneuploids (28). FLC is 
not sufficient to produce titan cells, and the mechanism through which FLC 
increases DNA content in vitro appears different from the ploidy increase seen in 
titan cells during infection.  However, FLC treated mice infected with C. albicans 
show morphologically changed yeast cells that likely stem from an inability to 
undergo cytokinesis (12). Isolates of C. neoformans obtained from clinical samples 
exhibit significant variation in susceptibility to FLC, and resistant clones with 
chromosomal disomy have been detected in brains of mice treated with FLC (29, 
30). Thus, our in vitro data suggest that during infection with C. neoformans, 
treatment with FLC may lead to an increase in DNA content in yeast cells through 
pleiotropic effects on cell division. Cells with increased DNA content would support 
microevolution of populations with an augmented potential to survive in the host 
environment.  
As discussed by Cheong and McCormack, several studies demonstrate 
conflicting results regarding the correlation between the MIC values for FLC in vitro 
and the clinical outcomes (31). The authors demonstrate that 30% of patients with 
cryptococcosis who have never been exposed to FLC provided evidence of 
reduced susceptibility to this antifungal (31). Desnos-Ollivier et al. have recovered 
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genetically related haploid and diploid strains from the same patients and 
demonstrated through experimental infections and quantitative PCR that ploidy 
changes can result from endoreplication and that switching between haploid and 
diploid states can occur, consistent with microevolution within the host (32). 
Therefore, it is plausible that stress conditions in the host stimulate an increase in 
DNA content through inhibition of cellular division similar to the effects of FLC in 
vitro described herein. Several genes have been described in S. cerevisiae that 
are essential for viability of polyploid cells (26). It would be of interest to test if 
homologues of these genes in C. neoformans are essential for viability of FLC-
derived polyploids and formation of FLC-resistant populations.   
 
MATERIALS AND METHODS 
Growth Conditions  
Strains used in this study are listed in Table 2.1. Unless otherwise stated, cells 
were grown in liquid YPD overnight at 24°C and refreshed next day to optical 
density at 600 nm (OD600) of 0.2 before treatment. For FLC-treated cultures, 50 
mg/ml FLC stock solution (Sigma, St. Louis, MO, or Alfa Aesar, Haverhill, MA) was 
prepared in DMSO. Spot assays were performed using a 10-fold serial dilution 
starting with 10,000 cells per 5 µL and ending with 10 cells per 5 µL. Cells were 
spotted on semi-solid YPD media or YPD media containing indicated concentration 
of FLC, incubated at room temperature, and imaged after three days.   
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Strain constructions 
All transformations were performed using biolistics transformation (33). The 
diploid, DSA3, was generated by mating a strain expressing nucleoporin Nup107 
tagged with GFP, LK315, (constructed as described earlier based on plasmid 
pCN19, (17)), with a strain expressing an endogenous histone H4 tagged with 
mCherry, CNV121 (34). The two strains were mixed on the mating MS agar 
medium and after 2 days cells were plated on double selection (NAT, HYG) media 
from which diploids were recovered. Diploid generation was confirmed using 
fluorescence microscopy and flow cytometry. Strain LC4 was generated by 
transforming LK315 with the plasmid LKB77 (19). Strain LK126, expressing GFP-
tagged beta tubulin (CNAG_01840) was generated by transforming strain H99 with 
the plasmid LKB37 (a pCN19-based plasmid expressing GFP-tagged beta tubulin 
from a constitutive histone H3 promoter). Strain LK65 (cdc3∆) is identical to 
previously published LK64 (17). 
 
Flow cytometry  
Cells were harvested before exceeding OD600 ~0.8, spun down, washed with sterile 
water, suspended in 100 µl distilled water, and fixed with 70% EtOH (in a drop wise 
manner while vortexing). Cells were then incubated at 24°C for 1 hour and 
transferred to 4°C overnight.  Next day, cells were washed with RNAse A buffer 
(0.2M Tris pH 7.5, 20 mM EDTA), suspended in 100 µl of RNAse A buffer with 1 
µl RNAse A (from 10 mg/ml stock), and incubated for 4 hours at 37°C. Cells were 
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then washed twice with 1 ml phosphate-buffered saline (PBS), suspended in 900 
µl of PBS, and incubated at 4°C overnight. Cells were stained with propidium iodide 
(PI) by adding 100 µl of 0.005 µg/ml PI stock and incubated in the dark for 30 
minutes. Immediately before analysis, cells were sonicated at 20% amplitude for 5 
sec. to avoid clumping.  
For ploidy analysis, the PI fluorescence was collected from 10,000 cells 
using FL3 (488 nm laser) on BD Accuri C6 flow cytometer. To assess the 
morphology of cells according to ploidy levels, cell sorting was performed using a 
Biorad S3E cell sorter. At least 500,000 cells were sorted into each fraction based 
on PI fluorescence and morphology of cells was assessed using the following 
categories: unbudded, normal budded, abnormal (wide neck) budded, and 
multimera.  
To assess FLC susceptibility of cell populations according to cell sizes, cell 
sorting based on size and complexity was performed using a Biorad S3E cell 
sorter. Cells from each fraction (R1, R2, and DMSO control) were scored based 
on morphology using the following categories: unbudded, budded, and multimera. 
Cells from each fraction were then plated on semi-solid YPD media containing 32 
µg/ml FLC and grown at 24°C for 6 days.  After 6 days, plates were imaged and 
areas of random 100 colonies were measured using ImageJ (35).  
For analysis of re-replication, unbudded cells were selected via modified 
centrifugation method based on a procedure described by Ayscough et al. (36). 
Cells were treated for 3 h with 32 µg/ml FLC or equivalent DMSO then pelleted 
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and suspended in 50% sorbitol (1M) and 50% YPD. Cells were spun at 2000 rpm 
for 5 min. The supernatant was transferred to a new tube and spun at 1500 rpm 
for 5 min. Again, the supernatant was transferred to a new tube and spun at 4000 
rpm for 10 min. The morphology of the pelleted cells was then assessed under the 
microscope to ensure the majority of the population was unbudded. Cells were 
released into DMSO or 32 µg/ml FLC. At various time points the morphology was 
checked to ensure that no multimera cells were present and the cells were fixed 
and stained with the PI for ploidy assessment using flow cytometry.  
 
Microscopy 
Bright field and fluorescence images were captured using the 100x objective with 
a Zeiss Axiovert 200 inverted microscope (Carl Zeiss, Thornwood, NY) interfaced 
with AxioVision Rel 4.8 software (Carl Zeiss, Thornwood, NY). Micromanipulation 
was performed using SporePlay dissection microscope (Singer Instruments, UK). 
Unless otherwise stated, images were processed in Adobe Photoshop (Adobe 
Systems Incorporated, San Jose, CA). Zen Blue (Carl Zeiss, Thornwood, NY) was 
used to measure the diameter of the bud of mitotic spindle containing cells. ImageJ 
(35) was used to measure H4-mCherry nuclear fluorescence. This was done by 
flattening the Z-sections to project the maximum intensities from each section and 
outlining the fluorescence of the nucleus. To account for DNA compaction, the 
pixel value of the outlined area was multiplied by the area. To establish a criterion 
based on which to group cells according to relative H4-mCherry fluorescence, we 
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first measured variation of the fluorescent signal in control cells (not exposed to 
FLC). Specifically, we found that the ratio of the fluorescent signal between the 
daughter and mother cell ranges between 0.7 and 1.6. Based on this variation, we 
decided a ratio of less than 0.7 and more than 1.6 to define less and more 
chromatin in the daughter as compared to the mother cell, respectively.   
For time-lapse analysis of components of cytokinesis, cells were pre-treated 
with 24 µg/mL FLC in YPD or yeast-nitrogen-base (YNB) medium with 2% glucose 
at 24°C for ~ 6 h. Subsequently, cells were transferred to YNB+2% glucose 
medium containing 24 µg/mL FLC (300 µl of 1.00 x 106 cells/mL cell suspension) 
and placed in a chamber of a borosilicate 8-chamber-slide (Bio-Tek, Winooski, 
VT).  At each time-point, 5 Z-sections spaced 1.20 µm apart were taken.  
To visualize chitin, calcofluor white staining was performed. H99 cells were 
grown in YPD and treated with either 24 µg/ml or 32 µg/ml FLC for 9 hours. Cells 
were then harvested, washed with YNB, and fixed with 3.7% formaldehyde for 1 
hour while culture was aerated. Cells were washed with PBS and permeabilized 
with 1% Trition-X (Sigma-Aldrich, St. Louis, MO) for 10 minutes. Finally, cells were 
incubated for 30 minutes after the addition of 1 µg/mL of calcofluor white (Sigma-
Aldrich, St. Louis, MO), washed, resuspended in YNB and visualized with the Zeiss 
Axiovert 200 inverted microscope.     
For evaluation of budding, cell surface was biotinylated using EZ-Link Sulfo-
NHS-LC-Biotin (ThermoScientific) and stained with ExtraAvidin (TM) 
tetramethylrhodamine (TRITC) (Sigma, St. Louis, MO). Cells were washed three 
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times with PBS and suspended to a density of 5x10^7 cells/ml. Subsequently, 4 
mg/ml of Sulfo-NHS-LC-Biotin reagent was added. Cells were incubated at 24°C 
for 30 minutes. Cells were washed three times with YPD. Biotinylated cells were 
released into 2 ml of YPD with DMSO or 32 µg/ml FLC and after three hours the 
cells were washed three times with PBS and incubated in the dark with TRITC 
(1:200) for 10 min. Cells were washed three times with PBS and imaged. The total 
number of cells was counted using the bright field. Then the number of new buds 
(buds that were not stained) were counted using the Rhodamine channel.  
To assess the effect of ergosterol exchange rate on budding inhibition, unbudded 
cells were selected via centrifugation (36). Cells were then incubated with either 
100 µm LatB (Enzo Life Sciences, Inc., Farmingdale, NY) or 100 µm LatB + 32 
µg/ml FLC for various time points. Cells were then washed and incubated for 3 
additional hours in DMSO or 32 µg/ml FLC. The percentage of budded cells was 
then estimated based on Bright field microscopy.  
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Figure 2.1. FLC treatment results in an increase in ploidy in a significant 
fraction of cells. C. neoformans cells treated with FLC were fixed, stained with 
propidium iodide (PI) and examined using fluorescence flow cytometry. Treatment 
of cells with 32 µg/ml FLC at 24°C for 12 and 14 hours resulted in ~20% and 88%, 
respectively, of the cell population with ploidy levels at or above 4n, as indicated 
by vertical line. 
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Figure 2.2. Treatment with FLC causes inhibition of budding. A) Schematic 
showing experimental procedure. After FLC treatment cell surface was stained 
with tetramethylrhodamine (TRITC). Stained cells were released into DMSO-
containing control medium or 32 µg/ml FLC medium and after three hours the cells 
were imaged. The total number of cells was counted using the bright field channel 
and the number of new buds (buds that were not stained) were counted using the 
Rhodamine channel. B) Analysis of new buds showed that after 6 and 9 hours of 
FLC treatment budding was significantly inhibited (p = 0.01). 
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Figure 2.3. Pretreatment of cells with FLC and actin inhibitor Latrunculin B 
leads to a delayed inhibition of budding by FLC. Schematic of methodology 
explains the experimental procedure. Unbudded cells were selected and then 
treated with either LatB or LatB+FLC. Cells were then washed and released into 
DMSO or 32 µg/ml FLC and budding was assessed. Treatment with LatB was used 
to assess the effect of the rate of ergosterol exchange on budding inhibition. 
Inhibition of budding was delayed during LatB + FLC treatment; unbudded cells 
that were treated with LatB + FLC took 14 hours for budding to be significantly 
inhibited.  
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Figure 2.4. FLC treatment leads to a defect in cell separation. Cells were 
treated with 32 µg/ml FLC for 10 hours, fixed and the DNA was stained with PI. 
Subsequently, cells were fractionated using a fluorescence assisted cell sorting 
(FACS) instrument. Fractions of cells with increasing ploidy were collected and 
morphology scored under the microscope. Fractions of cells with highest ploidy 
level were enriched in multimeric cells. Multimeric cells (purple) were either 
trimeras, with two daughter cells formed out of the mother cell, or contained an 
additional daughter (a granddaughter) grown out of one of the daughters (purple 
arrow).  
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Figure 2.5. A delay or complete block in cell separation during FLC treatment 
may lead to an increase in DNA content in unseparated cells. A) A population 
of pre-selected unbudded cells was incubated with 32 µg/ml FLC for 3 or 6 hours 
(times when no multimeric cells were formed) and the DNA content based on the 
PI staining was assessed using flow cytometry. After 6 hours of FLC treatment 
~50% of cells indicated DNA content above 2n with a predominant population 
(visible as a peak) that corresponded to cells with 3n DNA content. B) FLC 
treatment results in aberrant dynamics of the mitotic spindle. Localization of mitotic 
spindle in cells treated with 32 µg/ml FLC for 22 hours was analyzed based on a 
strain that expressed GFP-tagged beta tubulin (LK126). In control sample (DMSO), 
spindle was detected exclusively within daughter cells. In contrast, FLC-treated 
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cells that had detectable spindle were either unbudded or contained extremely 
small buds (C). The size of the daughter cell when spindle was visible was 
relatively uniform for the control treatment (DMSO), while the FLC-treated cells 
exhibited a broader range of sizes of daughter cells when spindle was visible (C). 
Bar represents 5 microns. 
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Figure 2.6. Analysis of centromere dynamics in FLC treated cells. A strain that 
expressed fluorescently-tagged centromeric histone variant, mCherry-Cse4, and a 
component of the nuclear envelope, GFP-Ndc1 (CNV111), was subject to 
treatment with 32 m g/ml FLC for 13 and 15 hours prior to imaging. Panels 1-5 
depict representative types of aberrations in Cse4 dynamics, including 
centromeres positioned at the mother bud neck (panels 1 and 4, arrows), clustered 
centromeres in unbudded cells or cells with small daughters (panels 2 and 3), two 
nuclei present in one mother cell (panel 3), and centromeres that appear outside 
of the nuclear area (panels 2 and 5). Bar represents 5 microns.  
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Figure 2.7. FLC does not significantly inhibit AMR assembly and 
constriction. A) Time-lapse microscopy was performed with strain LC4 
expressing GFP-Nup107 (to visualize the nuclear envelope, shown in green) and 
mCherry-Myo1 (to visualize the AMR, shown in magenta) after 6 hours of pre-
incubation with FLC. In the example shown, by 15 min of subsequent FLC 
treatment the AMR constricts (white arrowhead), and by 135 min a new bud starts 
to emerge (white arrow) with no detachment of the first daughter cell. B) A 
multimeric cell treated as in (A) was imaged and individual focal planes (Z-
sections) are shown to illustrate a lack of cytoplasmic connection (based on the 
cytoplasmic signal of the GFP-Nup107). In this cell, both of the daughter cells 
possess the septa separating them from the mother cell. C) Cell from (B) was 
imaged at an earlier time point when the second daughter has not developed a 
septum and therefore its cytoplasm is not yet separated from the mother. To 
assess separation of the cytoplasmic signal pixel brightness along a line 
perpendicular to the mother daughter axis was plotted for both daughters as 
shown. While the second daughter (top graph) shows a steady increase of 
fluorescence along the line drawn, the first daughter shows diminishment of the 
fluorescence in the area corresponding to the mother-bud neck suggesting 
discontinuous cytoplasm between the two cells. Bars represent 5 microns 
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Figure 2.8. FLC does not significantly inhibit AMR assembly and constriction 
and septin localization. A) To monitor constriction of the AMR, time-lapse 
microscopy was performed using a strain that expressed a component of the AMR, 
myosin heavy chain, Myo1, tagged with mCherry and a nucleoporin Nup107, 
tagged with GFP (to monitor the stage of mitosis, LC4). Cells from the control 
treatment (DMSO) have constricted the AMR. FLC-treated cells that formed 
multimeras also constricted the AMR, although the dynamics of the constriction 
varied significantly as compared to non-treated control cells. The arrow at 70 min 
indicates a dark line that likely corresponds to septum formed after the AMR has 
constricted. Bars represent 5 microns. B) Cells expressing septin Cdc10-mCherry 
(LK62) were pre-treated with 24 µg/ml FLC for 6 hours and the localization of 
Cdc10-mcherry was analyzed by time-lapse microscopy while the cells were 
continually exposed to FLC (time indicates progression of the time-lapse). Cdc10-
mCherry formed a collar and a double ring between the mother and the first 
daughter (arrow 1) and when the second daughter was formed (arrow 2). C) Cells 
deleted for Cdc3 or Cdc12-encoding genes (LK65, LK162) exhibited 
hypersensitivity to FLC with a clear defect in cytokinesis at 24°C (D). Bars 
represent 5 microns in A and B and 10 microns in D. 
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Figure 2.9. Analysis of the dynamics of Cts1 and deposition of the chitin in 
FLC treated cells. (A) and (B) depict cells expressing GFP-Cts1 and mCherry-
Myo1 (LK274) treated with 24 µg/mL FLC and imaged using time-lapse 
microscopy. A) Constriction of the actomyosin and Cts1 rings occur within 24 
minutes in the bud neck between the first daughter and mother cells (arrows). The 
first daughter cell fails to separate while a new bud emerges after 184 minutes (BF 
panel, arrow). Microtubule resembling structures of cts1 were seen (arrowhead). 
B) Formation of the cts1 ring follows that of the actomyosin ring. Constriction of the 
AMR takes place at 50 minutes while the constriction of the Cts1 ring follows 10 
minutes later. C) Cells treated with FLC for 9 hours were stained with calcofluor 
white and show the presence of chitin at the mother-bud neck of multimeric cells. 
Bars represent 5 microns. 
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Figure 2.10. FLC treatment results in an increase in ploidy in a significant 
fraction of diploid cells. Two haploid strains (Parent 1 – LK315 and Parent 2 – 
CNV121) and two diploids, a diploid derived from the two haploids (DSA3) and a 
reference diploid (Bt163), were treated with 32 µg/ml FLC, fixed, stained with PI, 
and passed through a fluorescence flow cytometer to assess ploidy. Both diploids 
underwent increase in ploidy analogous to the haploid strains (parents of derived 
diploid and wildtype), suggesting that 32 µg/ml of FLC imposes similar inhibitory 
effects on both haploids and diploids. Therefore, diploid is not significantly resistant 
to FLC as compared to the isogenic haploids. 
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Figure 2.11. FLC treatment leads to unequal distribution of chromatin 
between the mother and the daughter cells. Cells expressing histone H4-
mCherry from the endogenous promoter (CNV121) were treated with 32 m g/ml 
FLC for 12 hours and imaged using Z-section fluorescence microscopy. A total of 
44 multimeric cells were evaluated for the H4-mCherry signal in each of the cells 
constituting a trimera (M-mother, 1-first daughter, 2-second daughter). Cells were 
grouped depending on the relative amount of H4-mCherry fluorescence in each of 
the three cells as described in detail in materials and methods. The number of cells 
belonging to each category was counted as indicated. The meaning of each 
category is as follows: M >1,2 (more signal in the mother than in either of the 
daughter cells); 1,2 >M (more signal in either of the daughter cells than in the 
mother); 1,2>M>1,2 (one daughter with more and one with less signal than in the 
mother); 2=M=1 (all three cells with equal signal). Bar represents 5 microns. 
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Figure 2.12. FLC-treated cells that are enlarged and/or fail to separate are 
less sensitive to FLC. Cells were treated with 32 µg/ml FLC for 14 hours.  Two 
separate fractions were obtained based on size and complexity of morphology 
using FACS (fraction R1, R2). The morphology of each fraction was assessed. 
Fraction R1 consisted of predominantly unbudded cells with a smaller fraction of 
budded cells. Fraction R2 consisted of approximately equal amounts of unbudded 
cells, budded cells, and multibudded cells. Cells were then plated on media 
containing 32 µg/ml FLC, and the areas of colonies were measured after 3 days. 
Fraction R1 did not produce as many large colonies as fraction R2, suggesting the 
enlarged and/or multibudded cells are relatively less sensitive to FLC. 
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Figure 2.13. Microdissection of colonies grown on FLC media. Slightly 
enlarged budded or unbudded cells were placed on specific regions of a 32 µg/ml 
FLC plate using a micromanipulator. After 24 hours, 6 microcolonies derived from 
the enlarged cells were dissected separating each of the cells within a colony (2 
representative dissections are shown). The morphology of each cell at this point 
was assessed. Cells were then imaged at 36 and 48 hours time points and the 
number of resulting microcolonies was scored. Quantification of the 6 
microcolonies at 48 hours with respect to the initial morphologies of the cells at 24 
hours (after dissection) was performed as shown in the graph. Multimeric cells 
developed into significantly more microcolonies as compared to single-budded or 
unbudded cells. 
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Figure 2.14. A) Model illustrating the effects of FLC on cell growth, cell cycle 
progression and cytokinesis that result in cells with increased ploidy including 
single cells, multimeric cells, and cells with abnormal buds. According to this 
model, the resulting morphological defect for a given cell depends on the cell cycle 
stage when the cell was exposed to FLC initially. B) Model depicting progression 
of events that lead to formation of a multimeric cell during exposure to FLC. In this 
model, a multimera with equally distributed chromatin may transition to a stage 
when more chromatin is present in the mother cell as compared to daughters. 
While this seems to be the most prevalent type of multimeric cell, cells with other 
chromatin distribution and mother cells with two nuclei were also found (Figures 5 
and 7).   
. 
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Strain Genotype Source 
 H99  α WT (37) 
Bt163 Diploid; environmental isolate (38) 
CNV111 a GFP-NDC1:NAT + mCherry-CSE4:NEO  (13) 
CNV121 α H4-mCherry:NEO 
Sutradhar 
Sanyal ref 
DSA3 
a/a H4-mCherry:NEO/H4  GFP-
NUP107:NAT/NUP107 
This study  
LC4 a GFP-NUP1:NAT mCherry-MYO1:HYG This study  
LK62 a CDC10-mCherry:NEO (17) 
LK65 α CDC3::NAT (17) 
LK162 α CDC12::NEO (17) 
LK274 a GFP-CTS1:NAT mCherry-MYO1:HYG  (19) 
LK126 α GFP-TUB:NAT This study 
   
LK315 a GFP-NUP107:NAT This study 
 
Table 2.1. List of strains used in this study.  
 
 
 
 
 90 
REFERENCES 
 
1. Kwon-Chung KJ, Chang YC. 2012. Aneuploidy and drug resistance in 
pathogenic fungi. PLoS Pathog 8:e1003022. 
 
2. Morschhauser J. 2016. The development of fluconazole resistance in 
Candida albicans - an example of microevolution of a fungal pathogen. J 
Microbiol 54:192-201. 
 
3. Berman J. 2016. Ploidy plasticity: a rapid and reversible strategy for 
adaptation to stress. FEMS Yeast Res 16. 
 
4. Gerstein AC, Berman J. 2015. Shift and adapt: the costs and benefits of 
karyotype variations. Curr Opin Microbiol 26:130-136. 
 
5. Weaver BA, Cleveland DW. 2006. Does aneuploidy cause cancer? Curr 
Opin Cell Biol 18:658-667. 
 
6. Morrow CA, Fraser JA. 2013. Ploidy variation as an adaptive mechanism 
in human pathogenic fungi. Semin Cell Dev Biol 24:339-346. 
 
7. Lachaud L, Bourgeois N, Kuk N, Morelle C, Crobu L, Merlin G, Bastien 
P, Pages M, Sterkers Y. 2014. Constitutive mosaic aneuploidy is a unique 
genetic feature widespread in the Leishmania genus. Microbes Infect 
16:61-66. 
 
8. Selmecki A, Forche A, Berman J. 2010. Genomic plasticity of the human 
fungal pathogen Candida albicans. Eukaryot Cell 9:991-1008. 
 
9. Sionov E, Lee H, Chang YC, Kwon-Chung KJ. 2010. Cryptococcus 
neoformans overcomes stress of azole drugs by formation of disomy in 
specific multiple chromosomes. PLoS Pathog 6:e1000848. 
 
10. Morrow JD. 1991. Fluconazole: a new triazole antifungal agent. Am J Med 
Sci 302:129-132. 
 
11. Zhang YQ, Gamarra S, Garcia-Effron G, Park S, Perlin DS, Rao R. 2010. 
Requirement for ergosterol in V-ATPase function underlies antifungal 
activity of azole drugs. PLoS Pathog 6:e1000939. 
 
 
 
 91 
12. Harrison BD, Hashemi J, Bibi M, Pulver R, Bavli D, Nahmias Y, 
Wellington M, Sapiro G, Berman J. 2014. A tetraploid intermediate 
precedes aneuploid formation in yeasts exposed to fluconazole. PLoS Biol 
12:e1001815. 
 
13. Kozubowski L, Yadav V, Chatterjee G, Sridhar S, Yamaguchi M, 
Kawamoto S, Bose I, Heitman J, Sanyal K. 2013. Ordered kinetochore 
assembly in the human-pathogenic basidiomycetous yeast Cryptococcus 
neoformans. MBio 4:e00614-00613. 
 
14. Yoshida Y. 1988. Cytochrome P450 of fungi: primary target for azole 
antifungal agents. Curr Top Med Mycol 2:388-418. 
 
15. Yamaguchi M, Ohkusu M, Biswas SK, Kawamoto S. 2007. Cytological 
study of cell cycle of the pathogenic yeast Cryptococcus neoformans. Nihon 
Ishinkin Gakkai Zasshi 48:147-152. 
 
16. Altamirano S. CS, Kozubowski L. 2017. Mechanisms of cytokinesis in 
basidiomycetous yeasts. Fungal Biology Reviews. 
 
17. Kozubowski L, Heitman J. 2009. Septins Enforce Morphogenetic Events 
during Sexual Reproduction and Contribute to Virulence of Cryptococcus 
neoformans. Mol Microbiol. 
 
18. Fox DS, Cox GM, Heitman J. 2003. Phospholipid-binding protein Cts1 
controls septation and functions coordinately with calcineurin in 
Cryptococcus neoformans. Eukaryot Cell 2:1025-1035. 
 
19. Aboobakar EF, Wang X, Heitman J, Kozubowski L. 2011. The C2 
domain protein Cts1 functions in the calcineurin signaling circuit during high-
temperature stress responses in Cryptococcus neoformans. Eukaryot Cell 
10:1714-1723. 
 
20. Orlean P. 2012. Architecture and biosynthesis of the Saccharomyces 
cerevisiae cell wall. Genetics 192:775-818. 
 
21. Fernandez C, Lobo Md Mdel V, Gomez-Coronado D, Lasuncion MA. 
2004. Cholesterol is essential for mitosis progression and its deficiency 
induces polyploid cell formation. Exp Cell Res 300:109-120. 
 
22. Baker LG, Specht CA, Lodge JK. 2009. Chitinases are essential for sexual 
development but not vegetative growth in Cryptococcus neoformans. 
Eukaryot Cell 8:1692-1705. 
 
 92 
23. Banks IR, Specht CA, Donlin MJ, Gerik KJ, Levitz SM, Lodge JK. 2005. 
A chitin synthase and its regulator protein are critical for chitosan production 
and growth of the fungal pathogen Cryptococcus neoformans. Eukaryot Cell 
4:1902-1912. 
 
24. Walton FJ, Heitman J, Idnurm A. 2006. Conserved elements of the RAM 
signaling pathway establish cell polarity in the basidiomycete Cryptococcus 
neoformans in a divergent fashion from other fungi. Mol Biol Cell 17:3768-
3780. 
 
25. Mayer VW, Aguilera A. 1990. High levels of chromosome instability in 
polyploids of Saccharomyces cerevisiae. Mutat Res 231:177-186. 
 
26. Storchova Z, Breneman A, Cande J, Dunn J, Burbank K, O'Toole E, 
Pellman D. 2006. Genome-wide genetic analysis of polyploidy in yeast. 
Nature 443:541-547. 
 
27. Okagaki LH, Strain AK, Nielsen JN, Charlier C, Baltes NJ, Chretien F, 
Heitman J, Dromer F, Nielsen K. 2010. Cryptococcal cell morphology 
affects host cell interactions and pathogenicity. PLoS Pathog 6:e1000953. 
 
28. Gerstein AC, Fu MS, Mukaremera L, Li Z, Ormerod KL, Fraser JA, 
Berman J, Nielsen K. 2015. Polyploid titan cells produce haploid and 
aneuploid progeny to promote stress adaptation. MBio 6:e01340-01315. 
 
29. Venkateswarlu K, Taylor M, Manning NJ, Rinaldi MG, Kelly SL. 1997. 
Fluconazole tolerance in clinical isolates of Cryptococcus neoformans. 
Antimicrob Agents Chemother 41:748-751. 
 
30. Sionov E, Chang YC, Kwon-Chung KJ. 2013. Azole heteroresistance in 
Cryptococcus neoformans: emergence of resistant clones with 
chromosomal disomy in the mouse brain during fluconazole treatment. 
Antimicrob Agents Chemother 57:5127-5130. 
 
31. Cheong JW, McCormack J. 2013. Fluconazole resistance in cryptococcal 
disease: emerging or intrinsic? Med Mycol 51:261-269. 
 
32. Desnos-Ollivier M, Patel S, Spaulding AR, Charlier C, Garcia-Hermoso 
D, Nielsen K, Dromer F. 2010. Mixed infections and In Vivo evolution in 
the human fungal pathogen Cryptococcus neoformans. MBio 1. 
 
33. Davidson RC, Cruz MC, Sia RA, Allen B, Alspaugh JA, Heitman J. 2000. 
Gene disruption by biolistic transformation in serotype D strains of 
Cryptococcus neoformans. Fungal Genet Biol 29:38-48. 
 93 
 
34. Sutradhar S, Yadav V, Sridhar S, Sreekumar L, Bhattacharyya D, 
Ghosh SK, Paul R, Sanyal K. 2015. A comprehensive model to predict 
mitotic division in budding yeasts. Mol Biol Cell 26:3954-3965. 
 
35. Schindelin J, Rueden CT, Hiner MC, Eliceiri KW. 2015. The ImageJ 
ecosystem: An open platform for biomedical image analysis. Mol Reprod 
Dev 82:518-529. 
 
36. Ayscough KR, Stryker J, Pokala N, Sanders M, Crews P, Drubin DG. 
1997. High rates of actin filament turnover in budding yeast and roles for 
actin in establishment and maintenance of cell polarity revealed using the 
actin inhibitor latrunculin-A. J Cell Biol 137:399-416. 
 
37. Perfect JR, Ketabchi N, Cox GM, Ingram CW, Beiser CL. 1993. 
Karyotyping of Cryptococcus neoformans as an epidemiological tool. J Clin 
Microbiol 31:3305-3309. 
 
38. Lin X, Patel S, Litvintseva AP, Floyd A, Mitchell TG, Heitman J. 2009. 
Diploids in the Cryptococcus neoformans serotype a population 
homozygous for the alpha mating type originate via unisexual mating. PLoS 
Pathog 5:e1000283. 
 
 
 
 
 
 
 
 
 
 94 
CHAPTER THREE 
SINGLE CELL AND COLONY LEVEL ANALYSIS OF THE HETEROGENEOUS 
RESPONSE OF CRYPTOCOCCUS NEOFORMANS TO FLUCONAZOLE 
Sophie Altamirano, Charles Simmons, Lukasz Kozubowski 
Department of Genetics and Biochemistry, Clemson University, Clemson, South 
Carolina, USA 
 
 
 
 95 
ABSTRACT 
Cryptococcus neoformans is a human fungal pathogen that can cause fatal 
meningitis in immunocompromised individuals. Fluconazole (FLC) is a fungistatic 
drug administered to treat cryptococcosis. When exposed to the inhibitory 
concentration of FLC, C. neoformans exhibits heteroresistance where a small 
subpopulation of cells develops into FLC-resistant colonies. FLC-resistant cells are 
aneuploids with regard to specific beneficial chromosomal regions. Factors 
underlying the potential for only certain C. neoformans cells in a genetically 
isogenic population to become FLC-resistant are unknown. In this study, we 
systematically examine the heterogeneous response of C. neoformans to FLC at 
a colony and individual cell level. We find that the heterogeneity in response to 
FLC is reflected by variable diminishment of the ergosterol at the plasma 
membrane. A population of C. neoformans spread on a semi-solid medium 
displays two types of outcomes following FLC exposure. The first outcome is 
colonies consisting of non-resistant cells (survivors). The size of colonies 
consisting of survivors ranges from a few cells to visible colonies, which reflects 
intrinsic phenotypic heterogeneity of the C. neoformans population. The second 
outcome is FLC-resistant cells forming colonies of sizes significantly larger as 
compared to colonies made of survivors. We propose a model that describes how 
a distribution of these types of cellular responses within a population changes 
depending on FLC concentration and factors that influence the rate of cellular 
growth including temperature, media type, growth phase, and the age of cells. Our 
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findings highlight a complex nature of the response to a fungistatic drug and 
provide insights that may help to optimize FLC therapy. 
 
INTRODUCTION 
 
Single-cell clonal populations are made up of genetically homogeneous 
cells, but genetic identity does not necessarily translate to phenotypic similarity. 
Phenotypic heterogeneity has been shown to provide diversity among genetically 
clonal populations, allowing for adaptation to the environment without permanently 
locking the cells into a particular fate. It can be defined with respect to multiple 
aspects with various underlying physiological occurrences (1-4). Of particular 
importance is the heterogeneous response of pathogens to drug treatment, 
especially in the context of the development of drug resistance as it constitutes a 
major barrier to effective therapy.  
Drug therapies that aim at eliminating a certain cell type (i.e. microbial 
pathogens, cancer cells) often overlook the phenotypic heterogeneity that exists 
within the targeted cell population and its potential to promote survival during 
treatment. For example, one distinct challenge to antimicrobial therapy is the 
occurrence of “persister” subpopulations of slow growing cells, which contribute to 
recurrent infections (5). Persisters are thought to remain throughout infection; they 
do not make up the population of truly resistant cells, but may contribute to the 
formation of resistant cells through the ability to survive in the presence of the drug. 
Although more commonly studied in bacterial populations, the presence of 
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persisters has been characterized in several eukaryotic pathogens and cancer 
cells (5). An important question to consider when aiming at identifying a drug 
therapy that does not allow for resistance or recurrence is: Why are some 
genetically identical cells able to proliferate when challenged with a drug while 
others are inhibited? A better understanding of the intrinsic, phenotypic 
heterogeneity of cell populations is crucial to improve our current therapeutic 
approaches.  
In this study, we addressed the intrinsic heterogeneity within the population 
of Cryptococcus neoformans, a human fungal pathogen, in the context of the 
response to an azole drug, fluconazole (FLC) (6). FLC inhibits lanosterol 14α-
demethylase, Erg11p, which is an essential enzyme for the synthesis of ergosterol, 
an important sterol present in the cellular membranes and enriched in the plasma 
membrane (7). Previous studies have defined a phenomenon of heteroresistance 
in C. neoformans as an intrinsic ability to develop a small subpopulation of 
aneuploid, FLC-resistant cells, when exposed to the inhibitory concentrations of 
FLC (8-10). Specific genes that confer resistance to FLC in C. neoformans are well 
established (11, 12). On the other hand, mechanisms through which FLC 
potentially contributes to the development of resistance remain poorly 
characterized. Former studies have demonstrated that the response of C. 
neoformans to FLC is heterogeneous (8, 9). A plasticity of gene duplication 
patterns at the single colony level was observed, which suggested that the process 
of multiple chromosome duplication vary among individual cells (9). These findings 
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suggested that C. neoformans exhibits an inherent, non-genetic heterogeneity that 
influences the response to the drug. However, the nature of the heterogeneous 
response of C. neoformans to FLC has not been thoroughly investigated.  
We characterized the response of C. neoformans to FLC using colony and 
single-cell level analyses. We provide evidence that individual cells in the 
population exhibit variable diminishment of ergosterol within the plasma 
membrane during the initial exposure to FLC. This heterogeneity is reflected by 
the variable sizes of colonies that arise on a semi-solid medium supplemented with 
FLC. The resulting colonies can be divided into two groups: colonies that consist 
of non-resistant cells (survivors) and colonies that contain primarily resistant cells. 
Growth conditions that promote higher growth rate, including high nutrient content 
or higher temperature, lead to a diminishment of size of the colonies consisting of 
survivors and a decrease in number of resistant colonies in the presence of FLC. 
Conversely, conditions that lead to a slower growth rate, including nutrient poor 
media, lower temperature, and stationary phase of growth result in a more 
successful proliferation of survivors in the presence of FLC. Consistent with these 
results, relatively young cells form smaller colonies upon FLC exposure, as 
compared to the remaining population. Analysis of cell morphology indicates that 
conditions that promote slower growth may lead to a delay in daughter cell 
separation, which may contribute to a better survival in the presence of FLC. Based 
on our data, we propose a model, which describes how FLC concentration and 
temperature modulate distribution of colonies that contain non-resistant and 
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resistant C. neoformans cells. Our study provides insights that may help to improve 
in vitro drug susceptibility testing and augment treatments of cryptococcal 
infections.  
 
RESULTS 
Population of cells treated with fluconazole exhibits variable diminishment 
of ergosterol.  
The inhibitory effect of FLC has been associated with the depletion of ergosterol 
from the plasma membrane (13). Two non-exclusive possibilities may explain the 
heterogeneity of the response to FLC: 1) The degree of FLC-triggered depletion of 
ergosterol may vary from cell to cell or 2) The degree to which a cell is affected by 
a specific diminishment of ergosterol may vary from cell to cell. To test the first 
possibility, we utilized filipin as a proxy to estimate ergosterol levels in the plasma 
membrane of individual C. neoformans cells (14). As filipin exhibits high sensitivity 
to light and oxygen, imaging the samples separately could potentially lead to false 
interpretations of the data. To resolve this issue, we employed two strains, a wild 
type (H99) strain and H99-derived strain that expressed histone H4 tagged with 
mCherry (15). One of the strains was treated with FLC and the other served as a 
control. Prior to imaging, cells of the two samples were mixed, and filipin 
fluorescence was visualized for the mixed population. Scoring was executed taking 
into account mCherry fluorescent signal to differentiate between the samples 
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(Figure 3.1A). For each evaluation, we conducted two reciprocal experiments to 
account for possible differences between the strains used (Figure 3.1A and E).  
Untreated samples exhibited considerable variation in levels of filipin 
fluorescence between individual cells (Figure 3.1B, time 0). The variances for the 
two samples at time 0 were equal (at 0.05 significance level). A treatment with the 
inhibitory concentration of FLC (32 µg/ml) at 24°C caused an overall decrease of 
filipin fluorescence reaching an average fluorescence of ~56% of the control after 
4 hours (Figure 3.1B). Strikingly, after 4 hours of FLC treatment the variance of 
filipin signal among cells increased significantly as compared to the untreated 
control (443 vs 91; these variances are unequal at 0.05 significance level), as 
some cells showed almost no detectable filipin fluorescence while others showed 
fluorescence levels close to those of the non-treated control (Figure 1B). We also 
noted that at 4 hours of incubation over 50% of cells treated with FLC exhibited a 
non-uniform (patchy) fluorescence signal within the plasma membrane whereas 
less than 5% of control cells exhibited such irregular filipin fluorescence (Figure 
3.1C and D).  
Contrary to our expectation, treatment with FLC for 12 hours or longer 
resulted in a less significant overall diminishment of the filipin fluorescence and 
also a smaller percentage of cells with non-uniform filipin fluorescence within the 
plasma membrane, as compared to the 4-hour incubation (Figure 3.1A and D). In 
addition, differences in variance between the treated and the control sample were 
not significant for longer incubations except for 12 hours where variance for treated 
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sample was significantly higher (675 vs 82). These data suggest that ergosterol 
levels vary from cell to cell in untreated population. Furthermore, FLC, at inhibitory 
concentrations, causes considerable diminishment of ergosterol from plasma 
membrane after 4 hours of treatment and the effect is unequal between individual 
cells. Moreover, at the level of an individual cell, the depletion of ergosterol is non-
uniform within the plasma membrane with areas exhibiting more or less 
diminishment of ergosterol. Together, these results point to considerable variation 
of levels to which FLC affects individual cells in the population with respect to the 
ergosterol content.  
 
A non-resistant subpopulation of cells forms colonies under inhibitory 
concentration of FLC without the fitness cost.    
Our analysis of sterol content in plasma membrane of individual cells suggested 
that a cell population exhibits variable ergosterol content before drug exposure and 
unequal diminishment of ergosterol during response to the initial exposure to FLC. 
We would predict that variability in sterol content should be reflected by 
heterogeneity with respect to the growth rate in the presence of FLC. A simple way 
to probe for the heterogeneity of cell population with respect to growth rate is to 
analyze the sizes of individual colonies on a semi-solid medium. In order to analyze 
the heterogeneity in response to the drug, we applied FLC at 24 µg/ml, which is a 
concentration below the heteroresistance level of 32 µg/ml established for the 
strain we utilized (10).  
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An overnight culture plated on drug-free YPD rich semi-solid medium grew 
into colonies relatively uniform in size after 2-day incubation at 24°C (Figure 3.2, 
ON culture). An exposure of the same overnight culture to FLC at 24 µg/ml resulted 
in more variable colony sizes (Figure 3.2). After 5 days of incubation at 24°C, the 
effect of FLC ranged from a significant inhibition of proliferation (single cells or 
micro-colonies not visible by naked eye; data not shown) to growth retardation that 
resulted in visible colonies of various sizes (Figure 3.2).  
Did all colonies that were visible after 5 days on FLC-supplemented media 
contain cells that were resistant to FLC? To address this question, we picked at 
random 4 relatively small, and 4 relatively large colonies and re-plated the cells on 
media containing 24 µg/ml of FLC at 24°C. In addition, the same samples were 
also plated on YPD drug-free media to test for potential growth retardation that 
would be expected if the cells were aneuploids (9). Cells from all 4 small colonies, 
when re-plated on FLC-containing media resulted in colonies of various sizes and 
single cells after 5 days, indicating a range of inhibition characteristic of a 
population that is not resistant to the drug, although the visible colonies were 
relatively larger as compared to the initial culture plated on FLC media (Figure 3.2 
and data not shown). In contrast, cells from the large colonies grew significantly 
better on new FLC plates (Figure 3.2). Interestingly, when the distribution of colony 
sizes was assessed for the cells re-plated on the control YPD media, cells from 
three out of four large colonies grew relatively slower as compared to cells 
obtained from small colonies (Figure 3.2). Notably, cells from one large colony, 
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indicated as L3 in Figure 3.2, exhibited a fraction of colonies that were particularly 
large on FLC-supplemented media, while the majority of cells derived from this 
colony formed significantly smaller colonies on YPD-drug free media. Thus, for the 
cells derived from FLC-supplemented media, their ability to proliferate 
subsequently on new FLC-containing media correlates inversely with their 
proliferation rate on drug-free media. These results suggest that when the original 
overnight culture was spread on FLC-containing media only a fraction of colonies, 
likely the largest colonies, contained cells resistant to FLC used at concentration 
equal to 24 µg/ml, potentially through becoming aneuploids (as judged indirectly 
based on relatively slower growth on drug-free media). The remaining, smaller 
colonies represented cells that were not resistant to the drug yet managed to grow 
into visible colonies without a loss of fitness. We designate these non-resistant 
cells as survivors in contrast to cells that did not proliferate and truly resistant cells 
that formed relatively large colonies. Our data suggest that an asynchronous 
population of C. neoformans exhibits an intrinsic heterogeneity that is reflected by 
variable growth rate in the presence of FLC. Furthermore, upon exposure to a sub-
inhibitory concentration of FLC a fraction of the cell population develops into 
colonies that are not resistant to the drug yet manage to grow at a rate that is 
slower than resistant cells.  
 
C. neoformans cells display a normal distribution with respect to colony size 
on semi-solid, drug-free media.  
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What could account for the heterogeneity of response to FLC? Given that the 
variable response can be detected already after 4 hours of incubation with FLC 
(Figure 1), this heterogeneity is likely an intrinsic feature that characterizes the cell 
population prior to the drug exposure. Potentially such an intrinsic heterogeneity 
may be reflected by variable growth rates of individual cells even under 
unperturbed growth conditions. To examine this possibility, cells were spread on 
semi-solid rich YPD drug-free media, and the size distribution among randomly 
sampled ~100 micro-colonies detected under the microscope after 24 hours of 
incubation at 24°C was analyzed (Figure 3.3A). This analysis revealed that under 
drug-free conditions individual colonies of C. neoformans exhibit distribution of 
sizes that fits significantly to a normal distribution (R2 = 0.95). Accordingly, the 
population of cells contained two small subpopulations characterized by opposite 
extreme behaviors with respect to growth rate; a small fraction grew significantly 
slower and a second small fraction grew significantly faster as compared to the 
majority of cells in the population. Such a distribution of growth rates among the 
cells may reflect how the cell population would respond to FLC treatment.  
 
Rate of growth influences the response to FLC  
We hypothesized that the size of the colony that a given cell develops into in the 
presence of FLC correlates inversely with the rate of growth of a colony that would 
develop from this cell in drug free conditions. For example, a fraction of cells that 
are most successful in proliferating during the initial exposure to the inhibitory 
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concentration of FLC would be cells that are predisposed to exhibit relatively 
slower growth in drug-free conditions. If that were the case, we would predict that 
introducing conditions that normally (without the drug) promote slower growth 
should lead to an overall improved survival in the presence of FLC.   
Comparison of colony sizes indicated that cells incubated on drug-free 
semi-solid defined minimal media (YNB) proliferate significantly slower as 
compared to those cultured on rich YPD media (Figure 3.3A and B). Consistent 
with our hypothesis, plating cells on YNB minimal medium supplemented with 32 
µg/ml of FLC (YNB+FLC) led to a significant increase in the number and size of 
colonies as compared to the YPD supplemented with the same amount of FLC 
(YPD+FLC) (Figure 3.4A). Randomly picked, relatively large colonies grown at 
24oC on YPD+FLC media contained mostly resistant cells, as majority of these 
cells formed robust colonies when re-plated and incubated under the same 
conditions (Figure 3.4B). In contrast colonies randomly obtained from YNB+FLC 
media incubated at 24oC were not resistant to subsequent exposure to FLC in 
analogous conditions (Figure 3.4B). This suggests that the majority of colonies 
derived from the YNB+FLC plates are not resistant to FLC. Consistent with these 
findings, 4 out of 5 randomly picked large colonies from the YPD+FLC plates grew 
relatively slower when re-plated on the YPD drug-free media, whereas colonies 
obtained from the YNB+FLC plates contained cells that grew relatively better when 
spread on the YPD media (Figure 3.4B). These findings suggest that conditions 
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that promote slower growth lead to an increase in the number of colonies that 
contain non-resistant cells (survivors).  
Another condition that results in an overall lower proliferation rate is nutrient 
deprivation and increased cell density when the culture approaches stationary 
phase of growth. We tested whether incubation of cells without refreshing the 
medium would influence subsequent growth on media containing FLC. Strikingly, 
prolonged incubation of cells in liquid rich YPD medium before plating on FLC-
containing media led to an overall increase in colony number and size as 
compared to cells that were grown exponentially prior to FLC exposure (Figure 
3.4C). The effect was already observed for cells incubated for 2 days (data not 
shown) in liquid YPD prior to FLC treatment and was more pronounced for longer 
incubation times (Figure 3.4C). This result suggests that in contrast to cells at the 
exponential phase of growth, cells derived from a nearly stationary phase culture 
are relatively less sensitive to FLC and more likely to develop into colonies.  
Together our data suggest that external conditions that lead to an overall 
slower growth result in a better survival in the presence of FLC. We would predict 
that generating external conditions, which lead to an increased growth rate should 
elicit an opposite effect. One such condition is elevated temperature, which in case 
of C. neoformans results in increased proliferation rate. The intrinsic level of 
heteroresistance for the C. neoformans var. grubii (serotype A) strain H99 has 
been estimated at 32 µg/ml FLC at 30°C on semi-solid YPD media (10). We 
confirmed that when H99 cells were incubated with FLC under these conditions, 
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only a very small fraction developed into visible colonies (up to ~ 15 colonies were 
visible without magnification after 5 days on a plate on which ~ 10,000 cells were 
plated), in contrast to cells incubated at 24°C (Figure 3.4D compared to 3.4A). 
Consistent with previous reports, all of the visible colonies were resistant to the 
drug (most cells derived from a given colony grew upon subsequent plating on the 
same FLC concentration) and were likely aneuploids (most cells derived from a 
given colony grew slower on YPD drug-free media as compared to control cells, 
which were never exposed to the drug) (Figure 3.4E) (data not shown). These 
findings suggest that higher temperature leads to more susceptibility to FLC. 
Interestingly, cells derived from all randomly picked colonies that developed at 
30°C on YNB 32 µg/ml FLC media were resistant to the drug (Figure 3.4E). 
Notably, while the effect of YNB at 30°C was significant (more colonies as 
compared to YPD 32 µg/ml at 30°C), the number of visible colonies was 
significantly smaller as compared to YNB 32 µg/ml FLC plates incubated at 24°C. 
This result suggests that the higher temperature resulted in an overall lower 
percentage and a decrease in colony size of “survivors”, while maintaining (or 
potentially increasing) the number of resistant colonies. Consistent with these 
findings, higher temperature incubation also led to a decrease in colony numbers 
of cells derived from nearly stationary culture (Figure 3.4F).  
While 30°C has been established as a standard growth condition for drug 
susceptibility testing of C. neoformans, the temperature relevant to infection is at 
least 37°C (16). Therefore, we tested the effect of 37°C on colony growth in the 
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presence of FLC. When a culture that was maintained initially in drug-free liquid 
YPD media at 24°C was subsequently incubated on drug-containing YPD semi-
solid media at 37°C, a complete inhibition of growth was observed at a FLC 
concentrations as low as 1 µg/ml with no occurrence of resistance to the drug (out 
of 10,000 cells plated, no colonies were observed after 5 days at 37°C). Such a 
high sensitivity to FLC could stem from a synergistic effect between FLC and a 
significant and sudden change in temperature (from 24°C to 37°C) and media type 
(liquid to semi-solid). Indeed, when cells were initially grown for 24 hours at 37°C 
in liquid YPD drug-free media and subsequently incubated at 37°C on semi-solid 
media containing FLC, the concentration of 1 µg/ml was no longer inhibitory (data 
not shown). However, under those conditions the level of heteroresistance was 
estimated at ~5 µg/ml FLC, which is significantly lower than 32 µg/ml established 
at 30°C (data not shown).  
A previous study has suggested that already after ~ 10 hours of exposure, 
FLC leads to an increase in ploidy in a significant population of C. neoformans 
(17). Notably, we found that for a given concentration of FLC, the effect on ploidy 
was more significant with an increase in temperature (Figure 3.5). Together, these 
findings suggest that temperature is a critical factor that modulates the response 
of C. neoformans to FLC and influences the level of heteroresistance. These data 
are consistent with the important role of growth rate in the susceptibility to FLC. 
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Age of cells may be one of the intrinsic factors contributing to heterogeneity 
of the response to FLC. 
A culture of C. neoformans contains cells with various life spans. Therefore, age 
may potentially be one of the factors contributing to the heterogeneity in response 
to FLC. To test this possibility, we labeled cell walls with the fluorescent probe, 
Fluorescein Isothiocyanate (FITC), washed away the staining reagent, and 
incubated the culture for 3.5 hours in drug-free media such that the newly grown 
and detached daughters were no longer labeled. Next, cells that were FITC-
positive (a mix of cells with variable age) and FITC-negative (more homogenous 
with respect to age, relatively young cells) were separated using fluorescence-
assisted cell sorter (FACS). Subsequently, the separated fractions were plated on 
32 µg/ml FLC YPD semi-solid media and incubated at 30°C. Strikingly, in contrast 
to the mixed population, the “young” cells exhibited less heterogeneous response 
and were overall more sensitive to FLC as judged based on the distribution of 
colony sizes (Figure 3.6A). This finding suggests that the age of cells in the 
population is one of the factors contributing to the heterogeneous response to FLC. 
 
Multimera morphology is contributing positively to the survival in the 
presence of FLC. 
According to previous studies, C. neoformans cells that develop resistance to the 
initial inhibitory concentration of FLC are aneuploids typically with disomic 
chromosomes 1, and/or 4 (9). Studies in Candida albicans suggested that a 
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prerequisite to aneuploidy-derived resistance to FLC is the formation of aberrant 
multimeric cells that give rise to tetraploid populations, which subsequently 
undergo chromosomal loss (18). A recent study also demonstrates that FLC leads 
to cell separation defect followed by development of a second daughter cell, which 
results in formation of multimeric cells in C. neoformans (17). This study also 
reported that cells with increased ploidy and aberrant morphology exhibit overall 
improved growth in the presence of FLC (17). If the ability of C. neoformans to 
grow in the presence of FLC were dependent on the formation of multimeric cells, 
we would expect a correlation between the colony size and the presence of 
multimeric cells within a colony. In order to assess the response of individual cells 
to FLC, we plated cells on rich YPD media containing 32 µg/ml FLC, incubated at 
30°C for ~ 6 days, and evaluated growth under the microscope. Out of 10,000 cells 
that were plated, 12 colonies were visible consistent with previously established 
heteroresistance level (10). Microscopic observation of the remaining cells present 
on the medium revealed single cells as well as micro-colonies of various sizes. To 
gain more insight into the morphology of the cells we scored or dissected 100 
random cells or colonies, respectively, and analyzed cellular morphology of all the 
cells from each micro-colony (Figure 6B). Among 100 scored, we found four single 
cells suggesting that approximately 96% of cells that were originally plated have 
divided at least once within 6 days of incubation. These single cells exhibited 
normal morphology (were not multimeras). In contrast, microcolonies contained 
variable number of multimeric cells, which correlated with the colony size (Figure 
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3.6B; R2 = 0.77). Thus, our data suggest that formation of multimeric cells may 
promote proliferation and reflect the heterogeneity of the response to FLC.  
While the aneuploid state associated with the resistance is not stable, FLC-
resistant aneuploid cells should persist under the selective pressure of the drug 
(9). This may potentially indicate that the cells at the edge of the visible resistant 
colony grown under selective pressure of FLC should exhibit wild type morphology. 
However, the analysis of the edge of resistant colonies (found on YPD media 
containing 32 µg/ml FLC and incubated at 30°C for ~ 6 days) contradicted this 
possibility as it showed the presence of multimeric cells (data not shown). This 
finding was further supported by the flow cytometry analysis of sizes and the 
complexity of morphology of the cells derived from YPD plates supplemented with 
32 µg/ml FLC and incubated at 30°C. The results of this analysis suggest that both 
small (survivors) and large (resistant) colonies contain a significant fraction of 
enlarged and morphologically changed cells (data not shown). Thus, colonies 
consisting of resistant cells are morphologically heterogeneous suggesting that 
growth of the resistant colony involves a continual evolution of resistance based 
on formation of multimeric cells. While multimeric cells may not be sufficient for 
generation of FLC resistance, their formation may positively influence the survival 
of initially formed microcolonies in the presence of FLC.  
If multimeric cells were indeed contributing to a better survival in the 
presence of FLC, we would predict that conditions that lead to a delay in daughter 
cell separation (a phenomenon that leads to multimeric state) may promote 
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improved proliferation in the presence of FLC. Interestingly, a culture grown in YNB 
medium without FLC consisted of a significant number of multimeras at both 24°C 
and 30°C (Figure 3.7). Therefore, the increased survival on YNB semi-solid media 
may be due to increased multimera formation and may be common to other 
conditions that promote slow proliferation and improve growth in the presence of 
FLC. Alternatively, multimera formation could be a side effect of slow growth rather 
than a factor contributing to better survival. For instance, cells derived from nearly 
stationary culture are not multimeras (data not shown). Additionally, colonies 
grown on YNB semi-solid media at 30°C appeared to grow at approximately the 
same rate as cells grown on YPD semi-solid media at 24°C, which did not promote 
multimera formation (Figure 3.3C and D). These results suggest that while 
conditions that promote slower proliferation generally improve survival in the 
presence of FLC, the mechanisms through which this occurs may vary depending 
on a specific condition.  
 
DISCUSSION 
Our data and previous studies indicate that C. neoformans genetically 
homogenous population consists of cells that differ in their potential to proliferate 
when first exposed to FLC (9). We propose that this potential depends, at least in 
part, on the ability to retain ergosterol at the plasma membrane during FLC 
exposure. Most studies have assessed the effects of FLC on ergosterol levels after 
an overnight treatment with FLC. Moreover, the actual dynamics of the depletion 
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of ergosterol has not been well established in any model organism. Furthermore, 
most studies assessed the total amount of ergosterol extracted from an entire cell 
population. The only study that describes ergosterol content at the level of an 
individual cell assessed ergosterol levels based on the fluorescence of the sterol-
binding agent filipin in Penicillium discolor and Saccharomyces cerevisiae (14). 
Filipin staining utilized here as a proxy to assess the ergosterol content suggests 
an overall diminishment of plasma membrane ergosterol in FLC-treated 
populations that is non-uniform between individual cells. Interestingly, 
diminishment appeared also non-uniform within a single cell. Specifically, patches 
of higher fluorescence were distributed throughout the plasma membrane. This 
finding suggests that specific areas within the plasma membrane are more 
resistant to diminishment of ergosterol. One such area could be the sterol-rich lipid 
raft domains described previously in other cell types (19).  
At 12 and 24 hours of incubation with FLC the overall diminishment of 
ergosterol was less significant as compared to 4-hour time-point. One potential 
explanation could be that longer incubations may lead to a compensatory 
synthesis and incorporation of alternative sterols into the plasma membrane and 
an overall change in sterol composition (20). An alternative and non-exclusive 
possibility is that longer incubations lead to re-establishment of ergosterol in cells 
that have gained the resistance potential to continue proliferating in the presence 
of the drug. 
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The degree to which FLC affects the levels of ergosterol may depend on 
multiple factors, each characterized by a specific distribution within the population. 
In addition, factors independent of ergosterol levels may be involved. For instance, 
our other studies suggest that FLC treatment leads to an increase in Reactive 
Oxygen Species (ROS), which contribute to the inhibition of growth. Upon FLC 
exposure, individual cells within the population may vary in the levels of ROS. 
Similar to the retention of ergosterol, levels of ROS may also depend on multiple 
factors. In addition, we cannot exclude the possibility that the levels of ergosterol 
and ROS are interdependent.  
Based on our data and previous findings, we propose that each cell in the 
population is characterized by a net potential (derived from multiple factors) to 
proliferate in the presence of FLC. These potentials are specifically distributed 
among cells within the population. We postulate that the shape of this distribution 
will depend on intrinsic as well as extrinsic factors. Critical extrinsic factors that 
were characterized here include drug concentration, temperature, and the 
availability of nutrients. Our data suggest that an intrinsic factor that influences the 
response to FLC is replicative age of the cell. Specifically, a population consisting 
of mostly young cells exhibited a response that displayed relatively lower 
heterogeneity and an overall higher sensitivity to FLC. Interestingly, such a 
population still contains a small fraction of cells capable of becoming resistant to 
FLC. Consistent with our findings, it has been reported that C. neoformans cells 
that are old with respect to the replicative life span are more resistant to FLC (21).  
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As schematically depicted in Figure 3.8, at a given temperature, a 
population of cells that is treated with FLC is divided into those that do not grow 
into visible (by naked eye) colonies after ~ 5 days (significantly inhibited), those 
that form visible colonies consisting of non-resistant cells (survivors, depicted as 
green triangular line), and those that form colonies composed of mostly resistant 
cells (red line). As the concentration of FLC increases, the number and size of 
colonies consisting of survivors decrease until no visible colonies are observed 
even after ~5 days (FLC heteroresistance level, depicted as H). We postulate that 
colonies consisting of resistant cells appear only when the concentration of FLC is 
at a necessary minimum (depicted as R1). The number of resistant colonies 
reaches a maximum at the FLC concentration depicted as Rm. Based on our data, 
we propose that at concentration Rm, colonies of survivors are visible albeit their 
size is relatively smaller as compared to lower concentrations. According to this 
model, a minimum concentration of FLC at which survivors are no longer observed 
and resistant colonies are still present (depicted as H) is the heteroresistance level 
as described previously (10). Finally, at a concentration of FLC depicted as R2 no 
colonies are visible with a naked eye.  
While, according to this model, the size of colonies consisting of survivors 
decreases with increasing FLC concentrations (depicted as the width of the green 
triangular line), the size of colonies consisting of resistant cells is relatively uniform 
(red line), consistent with the definition of the resistant state. While our model 
depicts linear relationships between colony numbers (or colony size for the 
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survivors) and concentration of FLC, in reality these relationships are likely non-
linear. The exact function describing these relationships will depend on the nature 
of multiple factors (intrinsic and extrinsic) influencing cell growth in the presence 
of FLC.  
Our findings suggest that temperature is one of the critical extrinsic factors 
impacting the distribution of the potential to proliferate in the presence of FLC. 
Previous findings suggested that the susceptibility of C. neoformans to FLC 
increases with the elevation of temperature. Pettit et al. noted that biofilms formed 
by C. neoformans were more susceptible to FLC and the MIC’s of the planktonic 
yeast cultures were lower at 35°C as compared to 30°C (22). Mondon et al. 
demonstrated that a clinical isolate of C. neoformans fully resistant to 64 µg/ml 
FLC at 30°C forms a reduced number of colonies at 35°C, and no colonies at 37°C 
or 40°C (23). Our data suggest that the concentrations depicted in our model as 
R1, Rm, H, and R2 shift towards lower values as temperature of incubation 
increases (Figure 8). We propose that other factors will shift these concentration 
values in either of the two directions depending on the specific factor. Thus, these 
concentration values for a given population of cells under specific conditions would 
result from the net interaction between all factors.  
One factor that is influenced by various conditions (extrinsic and intrinsic) is 
rate of proliferation. Three extrinsic factors we analyzed in this study are 
temperature, the type of growth media (rich medium versus minimal medium), and 
the phase of growth (exponential versus stationary), all of which influence the 
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proliferation rate. Specifically, lower temperatures, higher cell densities (cells at or 
approaching stationary phase) and growth in minimal media (as opposed to rich 
media) result in an increase in the number and size of colonies consisting of 
survivors and resistant cells. Thus, for all three extrinsic factors studied here, the 
conditions that result in shift of concentrations R1, Rm, H, and R2 towards higher 
values are all associated with slower growth rate in drug free media, suggesting 
that conditions which result in slower growth/metabolism promote survival in the 
presence of FLC.  
Microbial pathogens may become less susceptible to an inhibition imposed 
by a drug through reducing the rate of the process that is the primary drug target 
(24). Such cells are not resistant to the drug, but they possess a better chance of 
survival during the initial exposure to the drug and therefore exhibit a higher 
chance to develop into drug resistant populations. While the effects of FLC are 
likely pleiotropic, a prominent result of FLC treatment in C. neoformans is inhibition 
of budding (17). It is therefore likely that conditions that promote slower growth 
result in less susceptibility to FLC. Alanio et al. showed that a subpopulation 
exhibiting slower growth rate, thought to be dormant cells, exist in vitro and in vivo 
in C. neoformans populations (25). These dormant cells could potentially promote 
survival during FLC treatment.   
Our data based on microscopic examination suggest that at concentrations 
of FLC depicted in our model as between R1 and R2, a large fraction of cells 
(increasing as the concentration of FLC approaches R2) form micro-colonies (not 
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visible by naked eye after ~ 5 days). These micro-colonies typically consist of 
multimeric cells, but the presence of multimeric cells does not ensure resistance. 
In fact, most of the cells that form multimeric micro-colonies do not gain true 
fluconazole resistance. Our data suggest that formation of multimeric cells is not 
sufficient to form a resistant colony under the inhibitory concentration of FLC. This 
however does not exclude the possibility that the formation of multimeras is 
necessary for the subsequent development of resistance. For instance, multimeric 
cells may promote sufficient proliferation to increase the number of stochastic 
events of aneuploidy formation out of which only a small percentage provides 
sufficient growth advantage and resistance to the particular concentration of the 
drug. Moreover, multimeras may be necessary for the maintenance of the resistant 
state. This is supported by the observation that multimeras are present at edges 
of the resistant colonies. This finding also suggests that a colony consisting of 
resistant cells is heterogeneous and contains cells at various resistance levels. It 
is possible that as the resistant colony grows, a continual process of gaining and 
losing the resistance continues within the colony, and a distribution of cells with 
various levels of resistance characterizes the colony.   
Recent findings suggest that in cancer cells exposed to an anticancer drug 
an epigenetic reprogramming takes place rendering a subpopulation of cells less 
sensitive to the drug (26). While our study suggests that a preexisting 
heterogeneity within the population of C. neoformans determines the response of 
individual cells to the drug, it is possible that in a population under specific growth 
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conditions and drug concentration, a subset of cells may possess the ability to 
divide and/or reprogram epigenetically, so that these cells lead to progeny able to 
acquire the resistant state subsequently. 
Grossman and Casadevall highlighted that C. neoformans undergoes 
unique changes during infection compared to laboratory in vitro conditions, making 
in vitro analyses suboptimal in predicting outcomes in infection models (27). Our 
study highlights another barrier to effective therapeutic strategies based on 
standardized in vitro susceptibility testing. The variability of the response to FLC 
due to extrinsic and intrinsic factors reported here should help to better understand 
phenotypic heterogeneity in C. neoformans and its role during FLC treatment. 
 
MATERIALS AND METHODS 
Growth Conditions  
Strains used in this study are Cryptococcus neoformans var. grubii wild type (H99) 
and an isogneic strain, in which a sequence encoding fluorescent protein mCherry 
was introduces to replace the STOP codon of the gene encoding histone H4 (28). 
Unless otherwise stated, cells were grown in liquid YPD overnight at 24°C and 
refreshed next day to 0.2 at 600 nm (OD600) before treatment. For FLC treated 
cultures, FLC (Alfa Aesar, Haverhill, MA) was prepared to a final concentration 
from a 50 mg/ml stock in DMSO. For experiments at 30°C or 37°C, cells were pre-
incubated in YPD overnight at 30°C or 37°C.  
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Flow cytometry  
Cells were harvested before exceeding ~0.8 OD600, spun down, washed with 
sterile water, suspended in 100µl distilled water, and fixed with 70% EtOH (in a 
dropwise manner while vortexing). Cells were then incubated at 24°C for 1 hour 
and transferred to 4°C overnight. Next day, cells were washed with RNAse A buffer 
(0.2M Tris pH 7.5, 20 mM EDTA), suspended in 100 µl of RNAse A buffer with 1 
µl RNAse A (10 mg/ml), and incubated for 4 hours at 37°C. Cells were then washed 
twice with 1 ml phosphate-buffered saline (PBS), suspended in 900 µl of PBS, and 
incubated at 4°C overnight. Cells were stained with propidium iodide (PI) by adding 
100 µl of 0.005 µg/ml PI stock and incubated in the dark for 30 minutes. 
Immediately before analysis, cells were sonicated at 20% amplitude for 5 sec. to 
avoid clumping. For ploidy analysis, the PI fluorescence was collected from 10,000 
cells using FL3 (488nm laser) on BD Accuri C6 flow cytometer. Cell sorting was 
performed using Biorad S3E cell sorter. At least 500,000 cells were sorted into two 
fractions based on cells labelled or not labelled with FITC using FL1 (488 nm laser).  
In order to separate young cells from the population, unbudded cells were 
selected via centrifugation. Cells were grown in 200ml for two days then pelleted 
and suspended in 50% sorbitol (1M) and 50% YPD. Cells were spun at 2000 rpm 
for 5 min. The supernatant was transferred to a new tube and spun at 1500 rpm 
for 5 min. Again, the supernatant was transferred to a new tube and spun at 4000 
rpm for 10 min. The morphology of the pelleted cells was then assessed under the 
microscope to ensure the majority of the population was unbudded. Cells were 
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then biotinylated using EZ-Link Sulfo-NHS-LC-Biotin (ThermoScientific) and 
stained with fluorescein (FITC) (Sigma, St. Louis, MO). Cells were washed three 
times with PBS and suspended to a density of 5x107 cells/ml. Subsequently, 4 
mg/ml of Sulfo-NHS-LC-Biotin reagent was added. Cells were incubated at 24°C 
for 30 minutes then washed three times with YPD. Biotinylated cells were released 
into YPD for an additional four hours and then washed three times and stained 
with FITC (1:200) for 10 minutes. Cells were then washed and released into PBS 
to be sorted.  
 
Microscopy 
Bright field and fluorescence images were captured using the 100x objective with 
a Zeiss Axiovert 200 inverted microscope (Carl Zeiss, Thornwood, NY) interfaced 
with AxioVision Rel 4.8 software (Carl Zeiss, Thornwood, NY). Micromanipulation 
was performed using SporePlay dissection microscope (Singer Instruments, UK). 
Unless otherwise stated, images were processed in Adobe Photoshop (Adobe 
Systems Incorporated, San Jose, CA). 
 
Ergosterol analysis at a single cell level 
Cells were harvested from liquid YPD, washed, and suspended in 1 ml PBS. Cells 
were then rotated in the dark with 5 µg/ml filipin III (Cayman Chemical, Ann Arbor, 
MI) for 5 min. Cells were allowed to settle for 5 min in chamber slide prior to 
imaging. Importantly, the total time in filipin stain did not exceed 15 min. To ensure 
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uniform filipin stain and to allow for comparison of treatments, wild type cells (H99) 
and cells expressing histone H4 tagged with the mCherry were incubated in 
conditions tested, and subsequently mixed together, and stained with filipin. 
Images were processed using ImageJ (https://imagej.nih.gov/ij/). To measure the 
intensity of filipin fluorescence, the plasma membrane marked by the filipin 
fluorescence was traced by a line 1 pixel thick, excluding an area where the 
daughter cell originates, and the intensity of each pixel was recorder along the 
traced line. Filipin value for each cell was calculated as an average of the pixel 
intensities from the entire traced line. To assess uniformity of the filipin signal along 
the plasma membrane section, images were assessed by 3 independent 
evaluators (who had no knowledge which cell in an image was treated with FLC 
and which one was the control) and cells were classified as either patchy or having 
a smooth filipin signal. All three evaluations were consistent indicating that 
classification of “patchy” was indeed based on a true difference between cells.     
 
ACKNOWLEDGEMENTS 
We thank Dr. Mariusz Dylag and Jessica Zielinski for help with the editing. 
This work was supported by the NIH grant (1R15 AI119801-01). We also thank 
Justin Scott from Clemson Light Imaging Facility (CLIF) for help with cell sorting. 
The research reported in this publication was conducted using a BioRad S3e cell 
sorter, housed in CLIF. CLIF is supported, in part, by the Clemson University 
Division of Research, NIH EPIC COBRE Award #P20GM109094, and NIH 
 123 
SCBiocraft COBRE Award #5P20RR021949-03.   The BioRad S3e cell sorter 
purchase was also supported in part with funds from the Air Force Office of 
Scientific Research (Award #FA9550-16-1-027007). The content of this material 
and any opinions, findings, conclusions, or recommendations expressed in this 
material is solely the responsibility of the author(s) and does not necessarily 
represent the official views of the National Institutes of Health or the United States 
Air Force.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 124 
 
Figure	1									
																		
		Figure	S1				
																									
E 
 125 
Figure 3.1. Unequal depletion of the plasma membrane ergosterol during 
FLC treatment. The fluorescent dye, filipin, served as a proxy to examine the 
effect of FLC on the ergosterol content in the plasma membrane at a single cell 
level. Cells were treated with 32 µg/ml FLC or DMSO as control for various 
hours, stained with filipin, and imaged immediately. A strain expressing histone 
H4-mCherry was treated with FLC, whereas a strain lacking nuclear fluorescence 
was treated with DMSO and served as a control. Prior to filipin staining the two 
strains were mixed in a 1:1 ratio. (A) Cells treated with FLC were recognized 
based on the H4-mCherry fluorescent signal (B) The average filipin fluorescence 
of cells treated with FLC exhibited increase in variability compared to DMSO 
treated cells. (C, D) FLC leads to a non-uniform depletion of sterol from the 
plasma membrane within a single cell. Filipin fluorescence was measured by 
tracing the fluorescent signal corresponding to the plasma membrane, and the 
intensity of the fluorescence of every pixel in the tracing path was plotted. Bar in 
A and C corresponds to 5 microns. (E)  The reciprocal analysis showing the 
average filipin fluorescence when H4-mCherry cells were treated with 32 µg/ml 
FLC and wildtype cells were treated with DMSO.  
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Figure 3.2. Heterogeneous response to FLC on a semisolid media. Cells from 
the overnight culture (ON culture) were spread on YPD semi-solid media and YPD 
media containing 24 µg/ml FLC and incubated at 24ºC. Cells incubated on FLC-
containing media produced colonies that varied in size after 5 days, whereas cells 
incubated on YPD drug-free media formed colonies more uniform in size (top two 
plates). Four small colonies (representative indicated by yellow square) and four 
large colonies (representative indicated by yellow circle) were randomly picked 
 127 
from the FLC-containing plate and spread on YPD control media or YPD media 
containing 24 µg/ml FLC. Plates were photographed (representative images are 
shown) and sizes of the resulting colonies from areas containing ~ 100 colonies 
were analyzed and plotted. Next to each plate a magnified area is shown. Cells 
obtained from the small colonies (black lines, s1-4) displayed similar colony size 
heterogeneity on FLC media compared to the initial population (ON) (left graph) 
and largely retained their ability to proliferate when grown on YPD (right graph). 
Cells derived from big colonies (grey lines, L1-4) displayed smaller colonies on 
YPD and larger, more homogenous colonies on FLC-containing media.  
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Figure 3.3. Cells not exposed to FLC exhibit a normal distribution of colony 
sizes. Cells were plated on YPD semi-solid media (A, C) or YNB semi-solid media 
(B, D) and incubated at either 24ºC (A, B) or 30ºC (C, D). The size of approximately 
100 colonies was measured and plotted against a normal distribution of numbers 
(correlation coefficient R2 indicates correlation between distribution of colony sizes 
and the normal distribution). Cells grown on YPD exhibited relatively larger 
colonies as compared to cells grown on YNB, and 30ºC led to relatively larger 
colonies as compared to 24ºC. 
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Figure 3.4. The response of FLC depends on temperature, media 
composition, and nutrient availability. (A, D) Incubation of cells on minimal 
medium YNB supplemented with 32 µg/ml FLC led to a significantly larger number 
of colonies at both 24ºC and 30ºC as compared to cells incubated on rich YPD 
media containing 32 µg/ml FLC. Incubation at 30ºC led to an increased FLC 
susceptibility on both YPD and YNB media as compared to 24ºC. (B, E) Five 
			Figure	4				
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relatively big colonies obtained from either YPD or YNB FLC-containing media 
(shown in A and D) were re-plated on YPD semi-solid media with and without 32 
µg/ml FLC. (C, F) Cells that were grown for 7 days in YPD liquid media without 
refreshing the media exhibited more colonies when subsequently spread on 
semisolid media containing 32 µg/ml FLC as compared to cells that were at the 
exponential phase of growth prior to FLC exposure. This effect was significant at 
both 24ºC and 30ºC.  
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Figure 3.5. Ploidy increase during FLC treatment is more severe in higher 
temperatures.  C. neoformans cells were treated with varying concentrations of 
FLC for various time points. They then were fixed, stained with propidium iodide 
(PI), and their DNA content was assessed using fluorescence flow cytometry. 
FLC treatment at 30ºC led to a more pronounced increase in ploidy compared to 
FLC treatment at 24ºC (RT).  
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Figure 3.6. (A) “Young” cells display more sensitivity towards FLC. Pre-
selected unbudded cells were biotinylated and released into YPD for four hours. 
Cells were then stained with streptavidin-conjugated FITC and sorted based on 
+FITC (older cells) or –FITC (young cells) signal. Young and older cells were 
spread on YPD media supplemented with 32µg/ml FLC, incubated at 30ºC, and 
after 6 days 100 colonies were dissected and number of cells in each colony was 
counted to assess degree of proliferation in the presence of FLC. The majority of 
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young cells display an overall higher sensitivity to FLC as compared to the mixed 
population. (B) Multimera morphology is not sufficient, but may be essential 
for the development of resistance to FLC. Cells were incubated on YPD 
media containing 32 µg/ml FLC at 30ºC for 6 days. 100 random colonies/cells 
were dissected and the number of normal and multimeric cells was counted in 
each micro-colony. 
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Figure 3.7. Incubation in minimal YNB media results in the formation of 
multimeric cells. Cells were incubated in YPD and YNB media at 24ºC and 30ºC 
and cellular morphology was assessed by flow cytometry and brightfield 
microscopy. A significant fraction of cells grown in YNB media exhibited multimera 
morphology, in contrast to cells incubated in YPD.  
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Figure 3.8. A model depicting the effects of the FLC concentration and the 
temperature on the distribution of two types of colonies of C. neoformans 
that are visible on semi-solid media. Green triangular lines illustrate colonies 
consisting of survivors, which are cells not resistant to FLC. Importantly, the 
thickness of the green line refers to the average colony size. The red line illustrates 
colonies consisting of mostly resistant cells. Specific concentrations of FLC 
included in the model are: R1 – minimum concentration at which resistant cells 
develop, Rm – concentration at which maximum resistant colonies develop, H – 
heteroresistance level (lowest concentration at which no survivors form visible 
colonies), R2 – lowest concentration at which no colonies are observed.  
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CHAPTER FOUR 
CONCLUSIONS AND FUTURE DIRECTIONS 
 
This work aims at defining the mechanisms of aneuploid formation in 
response to FLC and the underlying factors that play a role in the heterogeneous 
response to FLC in C. neoformans. The findings suggest that FLC treatment 
results in an initial increase in ploidy in a large percentage of cells. Based on our 
results, we hypothesize that FLC resistant aneuploids are selected from this 
population of cells exhibiting an overall increase in ploidy. This work also highlights 
several intrinsic and extrinsic factors that contribute to the heterogeneous 
response to FLC. 
Our data presented in Chapter 2 suggest that initial exposure to FLC inhibits 
budding and cell separation, which leads to the formation of multimeras that 
appear to be better equipped to proliferate in the presence of FLC. A major 
unanswered question that arises from this study is: Do multimeras occur during 
FLC treatment in vivo?  Given the increased survival of cells exhibiting the 
multimera morphology during FLC treatment in vitro, it would be interesting to 
further explore the role of multimeras in promoting infection during in vivo 
treatment. A previous study has shown that FLC heteroresistance and aneuploidy 
does occur in mouse models, but the morphology of the cells was never assessed 
(1). In addition to analyzing the morphology of cells during in vivo FLC treatment, 
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it would be intriguing to perform virulence testing on multimera cells to analyze 
their ability to promote infection and survive host environment and FLC treatment.  
Another major conclusion from the data presented in Chapter 2 is the lack 
of coordination between nuclear division and cellular growth in C. neoformans cells 
during FLC treatment. The process of cell cycle regulation and mitotic checkpoints 
are largely unknown in C. neoformans. The spindle assembly checkpoint (SAC) is 
a major mitotic checkpoint shown to prevent chromosome missegregation. SAC 
defects have been shown to be a major cause of aneuploid formation in cancer 
(2).  To further explore the effects of FLC on chromosome segregation, further 
studies could aim at characterizing the SAC pathway in C. neoformans and the 
potential effects of FLC on the SAC pathway.  
Although the effects of FLC described in Chapter 2 may be largely 
associated with defects at the plasma membrane level, we cannot exclude the 
possibility that the integrity of the nuclear envelope is also compromised due to 
FLC treatment. Such defects could lead to chromosomal instability. Indeed, our 
data indicating mislocalization of the centromeres is consistent with such a 
possibility. Utilizing a strain expressing mCherry-Cse4, to visualize the 
centromeres, and GFP-Ndc-1, to visualize the nuclear envelope, we provide 
preliminary evidence that FLC treatment may lead to “nuclear spillage” of 
chromosomes. These effects of FLC on the nuclear envelope could be further 
studied. Further microscopy, including confocal and electron microscopy, would 
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be needed to further characterize the occurrence of nuclear spillage during FLC 
treatment.   
In addition to the effects of FLC on the nuclear envelope, the indirect effects 
of FLC on chromosomal instability could also be further explored. Unpublished 
work from our lab suggests that FLC may indirectly increase DNA damage through 
upregulation of reactive oxygen species (ROS) and inhibition metallothionenin 
transcription. FLC treatment leads to DNA damage in vitro likely due to an increase 
of ROS in the presence of redox-active metals. Further studies assessing FLC 
potential to damage DNA in vivo could be further explored. Additionally, as 
previously seen in human cells, ROS accumulation may lead to SAC defects and 
subsequent aneuploid formation (3). Further analysis of the effects of ROS 
accumulation on the SAC pathway during FLC treatment would be of interest to 
explore.  
In Chapter 3, we describe the heterogeneous response of C. neoformans 
to FLC. We show that cells that exhibit slower growth are able to produce a 
population of cells that can grow during FLC treatment without becoming 
aneuploid. The mechanisms underlying increased survival in slow growers could 
be evaluated. One potential explanation for the increased survival of slow-growers 
during FLC treatment could be due to the decreased ATP production and 
mitochondrial function in slow-growing cells, as has been seen during persistence 
in bacterial populations (4). Consistent with this possibility, a study in Candida 
albicans shows that ATP levels serve as a good predictor for FLC susceptibility. 
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Populations of cells exhibiting higher ATP levels had lower minimum inhibitory 
concentration levels of FLC (5). Additionally, another study in C. neoformans 
showed that cells treated with tetracycline, a mitochondrial translation inhibitor, 
were more resistant to FLC. The correlation between ATP levels of individual cells 
and their survival in FLC could be further studied using the fluorescent ATP assay 
previously described by Kretschmar et al. (5).  
We show that extrinsic factors, such as: temperature, nutrient availability, 
and media composition affect the response of C. neoformans to FLC. We establish 
the initial rates of colony growth based on colony sizes fall under a normal 
distribution. It would be of interest to see how the rates of growth change during 
FLC treatment and how more physiological components contribute to FLC 
heterogeneity. A collaboration with a statistician to model population dynamics of 
FLC treated cells under various conditions would be critical for proper evaluation.  
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